SEARCH:      Monitor Keywords |  Custom RSS

Drug, bio-affecting and body treating compositions

20130123167 - Drug inhibiting the progression of atherosclerosis, preventive drug, blood cholesterol-lowering drug, functional food, and specific health food: Disclosed are a novel therapeutic agent and a novel prophylactic agent for atherosclerosis, a blood cholesterol level-lowering agent, and a functional food or a food for specified health uses effective for the inhibition and/or prevention of aging of blood vessels or inflammation in blood vessels. Specifically disclosed are an inhibitor... Agent: Jellice Co., Ltd.

20130123168 - Humanin and humanin-analogues for the management of atherosclerosis: The present invention is directed to methods and compositions for preventing or reducing atherosclerotic lesions and plaques. Specifically, the instant invention provides methods for using humanin and its analogues to prevent or reduce the formation of atherosclerotic plaques. Also provided are methods of using humanin and its analogues to improve... Agent: The Regents Of The University Of California

20130123170 - Growth hormone releasing peptides: e

20130123169 - Peptidomimetic macrocycles: The present invention provides peptidomimetic macrocycles capable of modulating growth hormone levels and methods of using such macrocycles for the treatment of disease.... Agent: Aileron Therapeutics, Inc.

20130123171 - Amide-based insulin prodrugs: Prodrug formulations of insulin and insulin analogs are provided wherein the insulin peptide has been modified by an amide bond linkage of a dipeptide prodrug element. The prodrugs disclosed herein have extended half lives of at least 10 hours, and more typically greater than 2 hours, 20 hours and less... Agent: Indiana University Research And Technology Corpora

20130123172 - Treatment of type 2 diabetes with fty720: The present disclosure provides therapeutic methods for prevention and treatment of type-2 diabetes comprising administering to the subject an effective amount of FTY720 or an analog.... Agent: Diapin Therapeutics LLC

20130123173 - Creation of oxidation-resistant hdl mimetic peptides: The present invention provides non-naturally occurring polypeptides that are oxidation resistant and have cholesterol efflux activity that parallels that of full-length apolipoproteins (e.g., Apo AI and Apo E), and having high selectivity for ABACI that parallels that of full-length apolipoproteins. The invention also provides compositions comprising such polypeptides, methods of... Agent: The Regents Of The University Of California

20130123174 - Neuritogenic peptides: The present invention relates to peptide compounds that are capable of stimulating neuronal differentiation, neurite outgrowth and survival of neural cells, and enhancing synaptic plasticity, learning and memory, methods of treating diseases and conditions of nervous system by administration of compositions comprising said compounds. The compounds and compositions of the... Agent: Neoloch Aps

20130123175 - Compounds for delivery of therapeutic and imaging moieties to nerve cells: where B is a binding agent capable of selectively binding to a nerve cell surface receptor and mediating absorption of the compound by the nerve cell; M is a moiety which performs a useful non-cytotoxic function when absorbed by a nerve cell, and can be a therapeutic moiety or an... Agent:

20130123176 - Compositions for regenerating defective or absent myocardium: Compositions of the invention for regenerating defective or absent myocardium comprise an emulsified or injectable extracellular matrix composition. The composition may also include an extracellular matrix scaffold component of any formulation, and further include added cells, proteins, or other components to optimize the regenerative process and restore cardiac function.... Agent:

20130123177 - Method of treating brain injury: A novel use of a neuropeptide for treating brain injury in a subject in need thereof is provided. The present invention also provides various amenable routes of administering urocortin, that is, via injection intracerebroventricularly and intraperitoneally, and via intravenous bolus administration.... Agent: Buddhist Tzu Chi General Hospital

20130123178 - Glucagon superfamily peptides exhibiting nuclear hormone receptor activity: Provided herein are glucagon superfamily peptides conjugated with NHR ligands that are capable of acting at a nuclear hormone receptor. Also provided herein are pharmaceutical compositions and kits of the conjugates of the invention. Further provided herein are methods of treating a disease, e.g., a metabolic disorder, such as diabetes... Agent: Indiana University Research And Technology Corporation

20130123179 - Fast dissolving pharmaceutical composition: The subject invention is directed to a pharmaceutical composition comprising an open matrix network carrying a pharmaceutically active ingredient, wherein the open matrix network comprises levan.... Agent: Ferring B.v.

20130123180 - Fast dissolving pharmaceutical composition: The subject invention is directed to a pharmaceutical composition comprising an open matrix network carrying a pharmaceutically active ingredient, wherein the open matrix network comprises inulin.... Agent: Ferring B.v.

20130123181 - Factor viii t cell epitope variants having reduced immunogenicity: Provided herein are methods and compositions for preventing or reducing an initial immune response to factor VIII in patients suffering from hemophilia A, and for reducing the intensity of the immune response in patients having pre-formed inhibitor antibodies against factor VIII.... Agent:

20130123182 - Identification and molecular characterisation of proteins, expressed in the ixodes ricinus salivary glands: The invention relates to a new polynucleotide which encodes a polypeptide expressed in the salivary glands of ticks, more particularly the Ixodes ricinus arthropod tick, during the slow-feeding phase of the blood meal have, said polynucleotide and related polypeptide may be used in different constructions and for different applications which... Agent: Henogen S.a.

20130123183 - Anti-tumor fibrillar human serum albumin methods and compositions: Fibrillar human serum albumin was shown to be effective in the treatment of various types of cancers. Methods and compositions are disclosed for using fibrillar human serum albumin as a medicament to treat subjects having cancer.... Agent: Academia Sinica

20130123184 - Methods for increasing levels of human fetal hemoglobin: The invention provides methods for increasing the level of human fetal hemoglobin in a subject or cell in need thereof. The methods can be used with subjects suffering from a β-chain hemoglobinopathy including thalassemia (e.g., β-thalassemia) or sickle cell anemia.... Agent: Celgene Corporation

20130123185 - Methods of treating and diagnosing acute chest syndrome: In certain embodiments, the disclosure relates to methods of treating or preventing organ inflammation or failure such as pulmonary inflammation comprising administering a heme scavenger such as hemopexin to a subject in need thereof. The subject may be diagnosed with higher than normal levels of protein-free plasma heme or a... Agent: Emory University

20130123186 - Neuroprotection using nap-like and sal-like peptide mimetics: This invention relates to NAP-like and SAL-like peptide mimetics, polypeptides, or small molecules derived from them, and their use in the treatment of neuronal dysfunction, neurodegenerative disorders cognitive deficits, neuropsychiatric disorders, and autoimmune disease.... Agent: Ramot At Tel-aviv University Ltd.

20130123187 - Peptides for the regulation of neurotransmitter sequestration and release: i

20130123188 - Methods for diagnosing and treating alzheimer's disease (ad) using the molecules that stabilize intracellular calcium (ca2+): The subject technology relates, in part, to a method of treating Alzheimer's Disease (AD), early-stage AD, elevated risk of AD, mild cognitive impairment (MCI), or other forms of age-related cognitive decline in a subject in need thereof by administering to the subject a molecule that promotes calcium-release stabilization in ryanodine... Agent: University Of Kentucky Research Foundation

20130123189 - Determination of single nucleotide polymorphisms useful to predict response for glatiramer acetate: e

20130123190 - Methods for treating combined radiation and thermal injury: The present invention provides methods for treating a subject that has suffered combined exposure to total body ionizing irradiation and burns.... Agent: University Of Southern California

20130123191 - Methods of inhibiting photoreceptor apoptosis: The present invention provides methods to prevent photoreceptor death. In particular, the present invention provides peptides which prevent FAS-mediated photoreceptor apoptosis.... Agent:

20130123192 - Compositions and methods for inhibiting matrix metalloproteinase (mmp)-mediated cell migration: The invention provides peptides, portions and derivatives thereof, that are useful for reducing cell migration, and for reducing symptoms of pathological diseases that are associated with undesirable cell migration, and in particular MMP-induced cell migration. This invention also provides peptides that are useful for detecting (e.g., imaging) cancers.... Agent: The Research Foundation Of State University Of New York

20130123194 - Autoclavable suspensions of cyclosporin a form 2: Disclosed herein are autoclavable formulations of cyclosporin A Form 2, methods of making such formulations, and methods of treating diseases of the eye with such formulations.... Agent: Allergan, Inc.

20130123193 - Cyclosporin a form 2 and method of making same: Disclosed herein are methods of making cyclosporin A Form 2.... Agent: Allergan, Inc.

20130123195 - Sustained action formulation of cyclosporin form 2: Disclosed herein are methods of treating diseases of the eye by administering to the subconjunctival space a formulation comprising cyclosporin A form 2 and a hydrogel.... Agent: Allergan, Inc.

20130123197 - Crystal of peptide substance as well as the preparation method and use thereof: The present invention discloses a crystal of a peptide substance and the preparation method as well as the use thereof. Said crystal B possesses peaks at the following 2θ angles in the X-ray diffraction pattern (XRPD): 3.2±0.2°, 5.4±0.2°, 6.2±0.2°, and 9.3±0.2°.... Agent:

20130123196 - Thioether-, ether-, and alkylamine-linked hydrogen bond surrogate peptidomimetics: Provided herein are peptidomimetics and their salts having a stable, internally constrained protein secondary structure containing a thioether-, ether-, or alkylamine-linked hydrogen bond surrogate; compositions containing at least one of these, and methods of making and using these.... Agent: New York University

20130123200 - Mammalian cell surface antigens; related reagents: Purified genes encoding a T cell surface antigen from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding this antigen are provided. Methods of using said reagents and diagnostic kits are also provided.... Agent: Merck Sharp & Dohme Corp.

20130123198 - Modulation of scleraxis using a dominant negative scleraxis mutant with a basic dna-binding domain deletion: Compositions and kits for modulating expression of scleraxis and/or collagen synthesis in mammalian cells and tissues. The compositions and kits comprise a protein comprising an amino acid sequence that shares at least 75% homology with SEQ ID NO:11. Proteins comprising amino acid sequences that share at least 75% homology with... Agent: University Of Manitoba

20130123199 - Protein complex for intracellular delivery and uses thereof: A protein complex comprising an in vitro stabilization protein, a membrane translocation sequence domain, a biologically active molecule, and an in vivo stabilization protein, as well as methods for the use and production thereof.... Agent: Samsung Electronics Co., Ltd.

20130123201 - Modulation of cytokine-induced chronic inflammatory responses: A composition for treatment of a chronic inflammation condition or an autoimmune disorder wherein the composition comprises a therapeutically effective amount of a polypeptide molecule comprising an amino acid sequence that shares at least 80% sequence identity with an amino acid sequence selected from SEQ ID NO: 21, SEQ ID... Agent: University Of Manitoba

20130123202 - Compositions and methods for treating aids or cancer by inhibiting the secretion of microparticles: Novel peptides that inhibit the release of microparticles from cells are disclosed. The peptide contains at least one VGFPV motif at the N-terminal and has a length of 10-100 amino acids. Also disclosed is polynucleotide encoding the peptide, expression vectors carrying the polynucleotide, and methods for treating AIDS and tumors... Agent: Morehouse School Of Medicine

20130123203 - Methods and compositions for treatment of autism: Disclosed herein are methods and compositions for treating autism. Disclosed herein are methods and compositions for treating an autism spectrum disorder.... Agent:

20130123204 - Method for treating hepatitis b: wherein R1 is OCH3, R2 is OH and R3 is H, or R1 is OH and R2 and R3 both are H, or R1 and R2 both are OH and R3 is H, or R1, R2 and R3 all are OH, and R4 is 3-(α)-OH, 3-(β)-OH, 3-(α)-O-sugar or 3-(β)-O-sugar. Bonding... Agent: Industrial Technology Research Institute

20130123205 - Antifungal and antiparasitic polyene macrolides: In certain aspects, the present disclosure provides for novel, water-soluble polyene macrolides and salts or solvates thereof and methods of making the water-soluble polyene macrolides. Also provided are compositions and methods for inhibiting, preventing, and/or treating fungal and parasitic diseases in a subject.... Agent: Acea Biotech, Inc.

20130123206 - Treatment of metabolic syndrome and insulin resistance with citrus flavanones: Methods of treating metabolic syndrome and/or insulin resistance including administering a therapeutically effective amount of purified hesperidin, purified hesperetin, or a purified derivative or analog of either compound to a subject with metabolic syndrome or insulin resistance (alone or in the context of metabolic syndrome).... Agent:

20130123207 - Compositions containing resveratrol and nucleotides: A resveratrol-containing composition capable of providing a therapeutic benefit to a subject such as modulation of a biological activity, improving cell transplantation therapy, or improving macular degeneration or dystrophy treatments. The compositions comprise trans-resveratrol, a metal chelator, one or more additional antioxidants such as quercetin, gamma-tocotrienol, or apple polyphenols, allicin,... Agent: Resveratrol Partners, LLC

20130123327 - Combined use of prame inhibitors and hdac inhibitors: The invention relates to the cancer antigen PRAME (PReferentially expressed Antigen in MElanoma) and its use in a method of treatment of a tumour which comprises administering to a subject in need of treatment an effective amount of an inhibitor of PRAME, in combination with a second agent selected from... Agent:

20130123332 - Compositions and methods for inhibiting expression of mylip/idol gene: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the Mylip/Idol gene, and methods of using such dsRNA compositions to inhibit expression of Mylip/Idol.... Agent: Alnylam Pharmaceuticals, Inc.

20130123339 - Compositions and methods for silencing apolipoprotein b: The present invention provides compositions and methods for the delivery of interfering RNAs such as siRNAs that silence APOB expression in cells such as liver cells. In particular, the nucleic acid-lipid particles provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells such as... Agent: Protiva Biotherapeutics Inc

20130123340 - Compositions and methods for the treatment and prevention of cardiac ischemic injury: Disclosed herein are compositions and methods for the treatment and/or prevention of pathological conditions associated with ischemia/reperfusion injury and/or hypoxic injury of myocardial cell or tissue.... Agent: University Of Medicine And Dentistry Of New Jersey

20130123330 - Dual targeted sirna therapeutics for treatment of diabetic retinopathy and other ocular neovascularization diseases: The present invention relates to compositions and methods for treating diabetic retinopathy and other ocular neovascularization diseases. In one embodiment, the composition comprises at least two different siRNA duplexes and a pharmaceutically acceptable carrier. One of the duplexes binds to an mRNA molecule that encodes VEGF, and the other binds... Agent:

20130123335 - Idh1 and idh2 mutations in cholangiocarcinoma: This document relates to methods and materials involved in assessing isocitrate dehydrogenase 1 (IDH1) or isocitrate dehydrogenase 2 (IDH2) mutations in a mammal (e.g., human). For example, this document provides methods and materials for diagnosis, characterization, determining prognosis, and treatment of cholangiocarcinoma tumor in a mammal.... Agent: Mayo Foundation For Medical Education And Research

20130123344 - Method of preventing or treating viral infection: wherein R1, R2, R3, R4, and R5 are as defined herein or pharmaceutically acceptable salts thereof. Also disclosed is a method of preventing or treating a viral infection of a host, comprising administering to the host an effective amount of an inhibitor of the JMJD2 family of histone demethylases, for... Agent: The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services

20130123345 - Method of treating a viral infection dysfunction by disrupting an adenosine receptor pathway: Described herein is a method of treating a viral infection such as an influenza infection, in a subject comprising administering an effective amount of a pharmaceutical composition to disrupt a adenosine receptor pathway, such as the Aradenosine receptor pathway, in a subject. The adenosine receptor pathway includes the steps of... Agent: The Ohio State University

20130123342 - Methods and compositions for the specific inhibition of kras by asymmetric double-stranded rna: This invention relates to compounds, compositions, and methods useful for reducing KRAS target RNA and protein levels via use of Dicer substrate siRNA (DsiRNA) agents possessing asymmetric end structures.... Agent: Dicerna Pharmaceuticals, Inc.

20130123328 - Methods and compositions for treating cancer: We describe a method of determining whether a cancer cell is likely to be resistant to treatment by an mTOR inhibitor. The method may comprise detecting PPP2R2B (GenBank Accession Number: NM_18167) in or of the cell. It may, alter-natively, or in addition, comprise detecting PDK1 (GenBank Accession Number: NM_002613), in... Agent: Agency For Science, Technology And Research

20130123343 - Methods for reverting methylation by targeting methyltransferase and compositions useful therefor: Methods for restoring a desired pattern of DNA methylation, inducing re-expression of methylation-silenced tumor suppressor genes (TSGs), and/or inhibiting tumorigenicity both in vitro and in vivo in a subject in need thereof by administering an effective amount of one or more miR-29s sufficient to target one or more of DNMT3A... Agent: The Ohio State University

20130123341 - Methods, compositions and kits for diagnosing and treating alzheimer's disease using mitochondrial co3 gene mutations: Methods and kits are provided for diagnosing, prognosing and treating Alzheimer's disease (AD) by identifying heteroplasmic mitochondrial mutations in cytochrome c oxidase subunit 3 (CO3). The methods are efficient, economical, and rapid, for diagnosis, prognosis and subsequent early treatment of AD in subjects.... Agent: University Of Virginia Patent Foundation

20130123329 - Microrna compositions and methods: Provided herein are compositions comprising oligomeric compounds. In certain embodiments, the oligomeric compounds are useful as miRNA mimics. The oligomeric compounds may mimic the activity of miR-34. Also provided herein are methods for the treatment of cancer.... Agent:

20130123331 - Modulation of diacylglycerol acyltransferase 2 expression: Compounds, compositions and methods are provided for modulating the expression of diacylglycerol acyltransferase 2. The compositions comprise oligonucleotides, targeted to nucleic acid encoding diacylglycerol acyltransferase 2. Methods of using these compounds for modulation of diacylglycerol acyltransferase 2 expression and for diagnosis and treatment of diseases and conditions associated with expression... Agent: Isis Pharmaceuticals, Inc.

20130123338 - Novel cationic lipids and methods of use thereof: The present invention provides compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel cationic lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo. The compositions of the present... Agent: Protiva Biotherapeutics, Inc.

20130123334 - Novel sirna structures: The invention relates to siRNA compounds possessing novel sequences and structural motifs which down-regulate the expression of specific human genes. The invention also relates to pharmaceutical compositions comprising such compounds and a pharmaceutically acceptable carrier. The present invention also provides a method of treating and/or preventing the incidence or severity... Agent: Quark Pharmaceuticals, Inc.

20130123333 - Nucleic acid functionalized nanoparticles for therapeutic applications: Materials and methods for regulating gene expression using nanoparticles functionalized with antisense oligonucleotides are provided.... Agent: Northwestern University

20130123336 - Polyplexes of hydrophobically-modified sirna for delivery of sirna: The present invention provides compositions and methods for delivering nucleic acid molecules to a cell.... Agent: Board Of Regents Of The University Of Nebraska

20130123337 - Rnai inhibition of serum amyloid a for treatment of glaucoma: RNA interference is provided for inhibition of serum amyloid A mRNA expression in glaucomas involving SAA expression.... Agent: Novartis Ag

20130123349 - Aegyptin and uses thereof: The present invention relates to the discovery of the Aegyptin gene and Aegyptin protein, a molecule that interacts with collagen and inhibits platelet adhesion, activation and aggregation. Novel biological tools, prophylactics, therapeutics, diagnostics, and methods of use of the foregoing are also disclosed.... Agent: The Regents Of The University Of California

20130123348 - Compositions for regenerating defective or absent myocardium: Compositions of the invention for regenerating defective or absent myocardium comprise an emulsified or injectable extracellular matrix composition. The composition may also include an extracellular matrix scaffold component of any formulation, and further include added cells, proteins, or other components to optimize the regenerative process and restore cardiac function.... Agent: Francis Law Group

20130123347 - Fractalkine binding polynucleotides and methods of use: Provided herein are polynucleotides that bind to fractalkine. In one embodiment, a polynucleotide includes the polynucleotide sequence SEQ ID NO:1 or a sequence having at least 80% identity to SEQ ID NO:1. Also provided herein are structures that include such a polynucleotide present on its surface, including 2-dimentional and 3-dimentional... Agent:

20130123350 - Nucleic acid molecule capable of binding to c-met and use thereof: o

20130123346 - Synthetic constructs for polynucleotide & protein expression: The present invention features, inter alia, nucleic acid constructs that include nucleotide sequences for regulating the expression of a sequence of interest. The sequences in the construct are not naturally associated with one another (i.e., they are heterologous), and they include an enhancer comprising response elements (e.g. Tcf sites) and... Agent:

20130123208 - Method of treating multiple sclerosis with adenosine receptor agonists: The present invention includes a composition comprising an A2A agonist. The present invention also includes a method of treating or reducing the symptoms of a neuroinflammatory disease in a patient in need thereof, wherein the method comprises administering to the patient a therapeutically effective amount of an A2A agonist. In... Agent: The Regents Of The University Of Colorado, A Body Corporation

20130123209 - Methods of treating hepatic encephalopathy: The application describes treatment of hepatic encephalopathy using gastrointestinal specific antibiotics. One example of a gastrointestinal specific antibiotic is rifaximin. The instant application also provides methods for determining if a subject has a neurological condition or hepatic encephalopathy by determining the critical flicker frequency and/or the venous ammonia level of... Agent: Salix Pharmaceuticals, Ltd

20130123212 - Anti-fatigue composition, formulation and use thereof: An anti-fatigue composition consisting of 20(S)-protopanoxadiol and lycium barbarum polysaccharide. Experiments prove that the composition exhibits a significant anti-fatigue effect. In comparison with the effect attained by the single use of lycium barbarum polysaccharide or 20(S)-protopanoxadiol, the combined use of 20(S)-protopanoxadiol and lycium barbarum polysaccharide exerts an obvious a clear... Agent:

20130123210 - Dermal filler compositions including antioxidants: Provided are injectable, hyaluronic acid-based hydrogel compositions including conjugated vitamins.... Agent: Allergan, Inc.

20130123211 - Pectic enzyme treated pectin, method of producing the same and application thereof: A pectic enzyme treated pectin (PET-pectin) and a method of producing the same are disclosed. Citrus pectin solution is subjected to an enzymatic hydrolysis by using a mixed pectinase solution under an acidic condition, so as to obtain PET-pectin that is completely hydrolyzed. The PET-pectin has several biological functions, including... Agent:

20130123213 - Modified starch material of biocompatible hemostasis: A modified starch material for biocompatible hemostasis, biocompatible adhesion prevention, tissue healing promotion, absorbable surgical wound sealing and tissue bonding, when applied as a biocompatible modified starch to the tissue of animals. The modified starch material produces hemostasis, reduces bleeding of the wound, extravasation of blood and tissue exudation, preserves... Agent:

20130123214 - Use of delta tocopherol for the treatment of lysosomal storage disorders: This disclosure relates generally to the treatment of lysosomal storage disorders. Specifically, the disclosure relates to a novel use of delta tocopherol in the treatment of diseases and conditions related to lysosomal storage disorders. Included in the present disclosure is a method for the modulation of cholesterol recycling. Further, the... Agent: The United States Of America As Represented By The Secretary Department Of Hr

20130123215 - 2,5-dioxoimidazolidin-1-yl-3-phenylurea derivatives as formyl peptide receptor like-1 (fprl-1) receptor modulators: The present invention relates to novel 2,5-dioxoimidazolidin-1-yl-3-phenylurea derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide receptor like-1 (FPRL-1) receptor.... Agent: Allergan, Inc.

20130123216 - Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof: The present invention provides cyclic nitro compound, pharmaceutical compositions of cyclic nitro compounds and methods of using cyclic nitro compounds and/or pharmaceutical compositions thereof to treat or prevent diseases or disorders characterized by abnormal cell proliferation, such as cancer, inflammation, cardiovascular disease and autoimmune disease.... Agent: Radiorx, Inc., C/o Interwest Venture Partners

20130123217 - Tetracycline derivatives with reduced antibiotic activity and neuroprotective benefits: The present disclosure is directed to compositions and methods which utilize the tetracycline scaffold, preferably the scaffold of tetracycline or minocycline, and which significantly lack antibiotic activity. The compounds have neuroprotective attributes without interfering with the drugs capacity to pass through the blood brain barrier. These compounds have neuroprotective activity... Agent: Neumedics

20130123218 - Intravenous formulation with water-soluble cocrystals of acetylsalicylic acid and theanine: A method of treatment using a water-soluble cocrystal composition contains a quantity of acetylsalicylic acid and a quantity of a theanine enantiomer selected from an alpha variant of theanine or a beta variant of theanine or other form of theanine.... Agent: Theaprin Pharmaceuticals Inc.

20130123219 - 19-nor-steroid derivatives with a 15a,16a-methylene group and a saturated 17,17-spirolactone ring, use thereof, and medicaments containing said derivatives: The 15α,16α-methylene-17-hydroxy-19-nor-17-pregna-4-en-3-one-21-carboxylic acid γ-lactone derivatives of the present invention possess progestational efficacy. They have the general chemical formula I, in which Z is selected from the group comprising an oxygen atom, two hydrogen atoms, NOR and NNHSO2R, where R is hydrogen, C1-C10-alkyl, aryl or C7-C20-aralkyl, R4 is hydrogen or halogen,... Agent: Bayer Intellectual Property Gmbh

20130123220 - Stable topical composition and a process for producing a stable topical composition: The present invention is directed to a suitable topical composition for cosmetic, pharmaceutical or dermatological use. In a particular aspect, it is a stable nanoemulsion whose particles have a narrow size distribution range. In another particular aspect, the invention is directed to an improved process for producing said composition.... Agent: Evidence Solu&#xc7 &#xd5 Es Farmac&#xca Uticas Ltda Epp

20130123221 - Compositions and methods for the treatment of skin diseases: Provided herein are compositions, methods and devices for the treatment of skin diseases and disorders in an individual. Described herein are pharmaceutical compositions comprising a non-homogenous vehicle, an alcohol selected from ethanol, isopropanol or n-propanol, at least one excipient, and, optionally, at least one pharmaceutical agent. Additionally, methods are described... Agent:

20130123222 - Synergistic anti-cancer activity of sr16388 with anti-mitotic drugs: The invention provides methods and compositions for inhibiting tumor growth in a mammal. The methods comprise administering to the mammal a synergistic combination of (E)-3-hydroxy-21-[2′-(N,N-dimethylamino)ethoxy]-19-norpregna-1,3,5(10),17(20)-tetraene and a microtubulin inhibitor like paclitaxel or vincristine. The combination of the compounds more than additively inhibits growth of tumor cells.... Agent: Sri International, Inc.

20130123223 - 4-pregenen-11beta-17-21-triol-3,20-dione derivatives: The present invention relates to novel 4-pregenen-11β-17-21-triol-3,20-dione derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals, as modulators of glucocorticoid or mineralocorticoid receptors. The invention relates specifically to the use of these compounds and their pharmaceutical compositions to treat disorders associated with glucocorticoid or mineralocorticoid... Agent: Allergan, Inc.

20130123224 - Certain chemical entities, compositions, and methods: Chemical entities that are bufalin derivatives, pharmaceutical compositions and methods of treatment of cancer are described.... Agent: Suzhou Neupharma Co., Ltd.

20130123225 - Inhibition of bacterial biofilms with aryl carbamates: Disclosure is provided for carbamate compounds that prevent, remove and/or inhibit the formation of biofilms, compositions including these compounds, devices including these compounds, and methods of using the same.... Agent:

20130123226 - Pharamceutical compositions and methods of use 4-pregenen-11beta-17-21-triol-3,20-dione derivatives: The present invention relates to pharmaceutical compositions comprising 4-pregenen-11β-17-21-triol-3,20-dione derivatives, and their use as pharmaceuticals as modulators of the glucocorticoid receptors (GR) and/or the mineralocorticoid receptors (MR). The invention relates specifically to the use of these compounds and their pharmaceutical compositions to treat ocular conditions associated with the glucocorticoid receptors... Agent: Allergan, Inc.

20130123227 - Novel organo-palladium complexes: The present invention relates generally to novel complexes of palladium or a palladium salt, lipoic acid and a long chain fatty acid, where the palladium is bonded to lipoic acid via both sulfurs and carboxyl group oxygens of lipoic acid, and where the long chain fatty acid is bonded to... Agent:

20130123228 - Promoting axon regeneration in the adult cns through control of protein translation: Survival of, or axon regeneration in a lesioned mature central nervous system (CNS) neuron is promoted by (a) contacting the neuron with a therapeutically effective amount of an exogenous activator of protein translation; and (b) detecting the resultant promotion of the survival of, or axon regeneration in the neuron.... Agent: Children's Medical Center Corporation

20130123229 - Cb1 receptor antagonists and uses thereof: Neutral antagonists of the CB1 cannabinoid receptor, means for identifying neutral antagonists of the CB1 cannabinoid receptor, and uses thereof. Antagonists of the CB1 cannabinoid receptor can be used to prevent, treat or reduce the severity of various medical conditions and symptoms, including, but not limited to obesity, appetite disorder,... Agent: Makscientific, LLC

20130123231 - Acc inhibitors and uses thereof: The present invention provides compounds useful as inhibitors of Acetyl CoA Carboxylase (ACC), compositions thereof, and methods of using the same.... Agent: Nimbus Apollo, Inc.

20130123234 - Aryl- or heteroaryl-substituted benzene compounds: The present invention relates to aryl- or heteroaryl-substituted benzene compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for... Agent: Epizyme, Inc.

20130123232 - Azetidinyl diamides as monoacylglycerol lipase inhibitors: e

20130123233 - Azetidinyl diamides as monoacylglycerol lipase inhibitors:

20130123235 - Tricyclic compounds and methods of making and using same: The invention provides tricyclic compounds and their use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making various tricyclic compounds are provided. The compounds are contemplated to have activity against methionyl aminopeptidase 2.... Agent:

20130123230 - 2-thiopyrimidinones: Myeloperoxidase inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, cardiovascular conditions.... Agent:

20130123237 - Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents: Novel compounds of structural formula (I) are activators of AMP-protein kinase and are useful in the treatment, prevention and suppression of diseases mediated by the AMPK-activated protein kinase. The compounds of the present invention are useful in the treatment of Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension.... Agent: Merck Sharp & Dohme Corp.

20130123236 - Substituted benzylspiroindolin-2-one analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m1: In one aspect, the invention relates to substituted benzylspiroindolin-2-one analogs compounds, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the muscarinic acetylcholine receptor M1 (mAChR M1); synthesis methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders... Agent: Vanderbilt University

20130123239 - Compounds having trpv1 antagonistic activity and uses thereof: The invention relates to compounds of Formula I and pharmaceutically acceptable derivatives thereof, compositions comprising an effective amount of a compound of Formula I or a pharmaceutically acceptable derivative thereof, and methods for treating or preventing a condition such as pain, UI, an ulcer, IBD and IBS, comprising administering to... Agent:

20130123238 - Use of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane to treat addictive and alcohol-related disorders: The present invention relates to (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane and pharmaceutically acceptable salts thereof, compositions comprising (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or a pharmaceutically acceptable salt thereof, and methods for treating or preventing an alcohol-related or addictive disorder. The (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or pharmaceutically acceptable salt thereof is preferably substantially free of its corresponding (−)-enantiomer... Agent:

20130123240 - Method of using biothionol and biothionol-like compounds as anti-angiogenic agents: The present disclosure relates generally to treating or preventing diseases associated with angiogenesis by administering to a patient certain compounds found to inhibit or substantially reduce angiogenesis. Compounds employed according to the present disclosure exhibit good anti-angiogenic activity as well as demonstrate a prophylactic effect for preventing and substantially reducing... Agent: Southern Research Institute

20130123241 - Novel ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments: The present invention relates to novel antagonists for CCR2 (CC chemokine receptor 2) of formula (I) wherein HET is a group selected from among formulas (IIa) (IIb) (IIc) (IId) and their use for providing medicaments for treating conditions and diseases, especially pulmonary diseases like asthma and COPD and pain diseases.... Agent: Boehringer Ingelheim International Gmbh

20130123242 - Compounds and methods for the treatment or prevention of flavivirus infections: e

20130123243 - Diamine derivatives as inhibitors of leukotriene a4 hydrolase: where r, q, R, R2, R3, R4, R5a, R5b, R5c, R6a, R6b, R6c, R7, R8, and R9 are described herein, as single stereoisomers or as mixtures of stereoisomers, or pharmaceutically acceptable salts, solvates, clathrates, polymorphs, ammonium ions, N-oxides or prodrugs thereof; which are leukotriene A4 hydrolase inhibitors and therefore useful... Agent: Celtaxsys, Inc.

20130123244 - Hetero-bicyclic derivatives as hcv inhibitors: e

20130123245 - Methods for alleviating chronic pain and improving performance of cattle undergoing dehorning or castration: Methods of improving performance, increasing weight gain, and decreasing incidence of disease in ruminant and pre-ruminant animals, such as cattle, after undergoing painful processing procedures, such as castration and dehorning, are provided. Veterinary formulations for use in methods of the invention are also provided. The formulations comprise a compound selected... Agent: Kansas State University Research Foundation

20130123246 - Modulators of indoleamine 2,3-dioxygenase and methods of using the same: The present invention is directed to modulators of indoleamine 2,3-dioxygenase (IDO), as well as compositions and pharmaceutical methods thereof.... Agent: Incyte Corporation

20130123247 - Arthropodicidal anthranilamides: e

20130123248 - Pharmacological modulation of positive ampa receptor modulator effects on neurotrophin expression: Antagonists of group 1 metabotropic glutamate receptors (mGluR) potentiate the effect of positive AMPA receptor modulators on neurotrophin expression, such as brain-derived neurotrophic factor (BDNF). The findings described herein suggest a combinatorial approach for drug therapies, using both positive AMPA receptor modulators and mGluR antagonists, to enhance brain neurotrophism.... Agent: The Regents Of The University Of California

20130123249 - Novel benzoxazine oxazolidinone compounds, preparation methods and uses thereof: Novel benzoxazine oxazolidinone compounds, preparation methods and uses thereof are disclosed, which belong to the field of pharmacy. More specifically, novel benzoxazine oxazolidinone compounds represented by the following general formula (I), preparation methods and uses thereof in preparing medicament for treating infectious diseases, especially infectious diseases caused by multi-drug resistant... Agent:

20130123251 - Benzoxazine derivatives and uses thereof: v

20130123250 - Spiro (piperidine-4,2'-pyrrolidine)-1-(3,5-trifluoromethylphenyl) methylcarboxamides as nk1 tachikynin receptor antagonists:

20130123252 - 2,3,5-trisubstituted thiophene compounds and uses thereof:

20130123253 - Modulators of central nervous system neurotransmitters: Disclosed are agents having pharmacological activity against cellular receptors and intracellular signaling, particularly receptors and signaling pathways of central nervous system (CNS) neurotransmitters. Also disclosed are related methods and compositions for the treatment or prevention of diseases or disorders using the agents.... Agent: Human Biomolecular Research Institute

20130123254 - Pharmaceutically acceptable mglur5 positive allosteric modulators and their methods of identification: The present invention relates to mGluR5 positive allosteric modulators (PAM) and methods for identifying pharmaceutically acceptable compounds with high tolerability and safety, which method comprises the use of at least one non-competitive mGluR5 allosteric modulator which has a shift factor measured at 10 uM glutamate concentration below 3.0,... Agent:

20130123255 - Combination of a pi3k inhibitor and a mek inhibitor: The invention relates to a method for the treatment of a patient with a proliferative disease including solid tumors, hematological malignancies and hyperplasia comprising administering a therapeutic combination to said patient wherein the therapeutic combination comprises a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable... Agent: Chugai Seiyaku Kabushiki Kaisha

20130123256 - Pyrazolo pyridine derivatives as nadph oxidase inhibitors: The present invention is related to pyrazolo pyridine derivatives of Formula (I), pharmaceutical composition thereof and to their use for the treatment and/or prophylaxis of disorders or conditions related to Nicotinamide adenine dinucleotide phosphate oxidase (NADPH Oxidase).... Agent: Genkyotex Sa

20130123257 - Quinoxalinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes: e

20130123258 - 4(1h)-quinolones having antimalarial activity with reduced chemical resistance: Provided are 4(1H)-quinolone derivatives effective in inhibiting or eliminating the viability of at least one of the stages in the life-cycle of the malarial parasite, and to show a reduced propensity to induce resistance to the compound by the target parasite. In particular, the compounds can be derivatives of phenoxyethoxy-quinolones,... Agent:

20130123259 - Substituted 3-(5-membered unsaturated heterocyclyl-1, 3-dihydro-indol-2-ones and derivatives thereof as kinase inhibitors: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.... Agent: Allergan, Inc.

20130123260 - Methods: The disclosure relates to compounds of formula (I) for use in the treatment or prophylaxis of rhinovirus infection, methods of treating or preventing rhinovirus infection employing said compounds or pharmaceutical composition comprising the same. The disclosure also relates to compounds of formula (I) for use in the treatment or prophylaxis... Agent: Respivert Limited

20130123261 - Isoxazoline compounds in type 2 diabetes and other maladies: Methods for treating diabetes in a subject, reducing the blood glucose level of a subject suffering from diabetes, and reducing or preventing an increase in the level of resistin in a subject, comprising administering to said subject a compound having the following formula: wherein R1, R2, R3, R4, R5, X,... Agent: Cpsi Stockholder Trust

20130123263 - Benzopyran and benzoxepin pi3k inhibitor compounds and methods of use: Benzopyran and benzoxepin compounds of Formulas I and II, and including stereoisomers, geometric isomers, tautomer solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using... Agent: Genentech, Inc.

20130123262 - Novel triazinedione derivatives as gabab receptor modulators: The present invention provides novel compounds of formula I wherein W1, W2, W3, W4, W5, B, X1, X2, X3, X4, X5, E and L are as defined herein; invention compounds are gamma amino butyrique acid receptor-subtype B (“GABAB”) positive allosteric modulators (enhancers), which are useful to provide methods of treating... Agent: Addex Pharma S.a.

20130123264 - Compositions and methods for treatment of inflammatory bowel disorders and intestinal cancers: Methods of using the compositions to treat intestinal and bowel diseases, and intestinal cancers, and methods of improving one or more physiological parameters of intestinal luminal integrity including, but are not limited to, reduced proliferation for example in the intestinal crypts, reduced apoptosis for example at the luminal surface, and... Agent:

20130123265 - Compounds that modulate intracellular calcium: Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of store-operated calcium (SOC) channels. Also described herein are methods of using such SOC channel modulators, alone and in combination with other compounds, for treating diseases, disorders or conditions that would benefit from inhibition of SOC... Agent: Calcimedica, Inc.

20130123266 - Treatment of a pathology linked to an excessive effect of tnf with a benzene sulphonamide compound: s

20130123267 - 1-pyridazinyl-hydroxyimino-3-phenyl-propanes:

20130123268 - 3,3-disubstituted-(8-aza-bicyclo[3.2.1]oct-8-yl)-[5-(1h-pyrazol-4-yl)-thiophen-3-yl]-methanones as inhibitors of 11 (beta)-hsd1: The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain 3,3-disubstituted-(8-aza-bicyclo[3.2.1]oct-8-yl)-[5-(1H-pyrazol-4-yl)-thiophen-3-yl]-methanone, 3,3-disubstituted-(6-aza-bicyclo[3.1.1]hept-6-yl)-[5-(1H-pyrazol-4-yl)-thiophen-3-yl]-methanone, and 4,4-disubstituted piperidin-1-yl)-[5-(1H-pyrazol-4-yl)-thiophen-3-yl]-methanone compounds of the following formula that, inter alia, inhibit 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1). The present invention also pertains to pharmaceutical compositions comprising such compounds, and... Agent: The University Of Edinburgh

20130123269 - Novel heterocycle compounds and uses thereof: e

20130123270 - Substituted piperazinyl-pyrrolidine compounds useful as chemokine receptor antagonists: or pharmaceutically acceptable salts thereof. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compounds and compositions for the inhibition of Chemokine Receptors and also for the treatment of various diseases, conditions, or disorders, including acute or chronic inflammatory disease, cancer or osteolytic bone... Agent: Millennium Pharmaceuticals, Inc.

20130123271 - Heterocyclic compounds, their preparation and therapeutic application: The invention is directed to certain novel compounds, methods for producing them and methods for treating or ameliorating a kinase-mediated disorder.... Agent: Fovea Pharmaceuticals

20130123272 - Organic compound for use in the treatment of liver cancer: The use of 4-amino-5-fluoro-3[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one or a pharmaceutically acceptable salt or a tautomer thereof, or a hydrate or a solvate for the manufacture of pharmaceutical compositions for use in the treatment of hepatocellular carcinoma or liver cancer.... Agent: Novartis Ag

20130123273 - Methods of targeting pten mutant diseases and compositions therefor: Provided herein are methods, uses and compositions for treating a patient with cancer wherein the cancer is characterized by a PTEN gene mutation. In particular embodiments, the methods comprise administering to the patient a composition comprising a therapeutically effective amount of a PLK4 antagonist, and identifying a patient that is... Agent: University Health Network

20130123274 - Antitumor agent using compounds having kinase inhibitory effect in combination: o

20130123275 - Pyrazine derivatives:

20130123276 - Use of telaprevir and related compounds in atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases:

20130123277 - Pyrido[3,4-b]indoles and methods of use: This disclosure relates to new heterocyclic compounds that may be used to modulate a histamine receptor in an individual. Pyrido[3,4-b]indoles are described, as are pharmaceutical compositions comprising the compounds and methods of using the compounds in the variety of therapeutic application, including the treatment of a cognitive disorder, psychotic disorder,... Agent: Medivation Technologies, Inc.

20130123278 - Pyrimidine derivatives and their use in the treatment of respiratory diseases such as copd: Compounds of formula (I) are inhibitors of neutrophil elastase, wherein A is C—R1 or N; -X1-X2- is CR15═N— or —NR19—CO—; and R1-R6, R15 and R16 are as defined in the claims.... Agent: Chiesi Farmaceutici S.p.a.

20130123279 - Crystal of thienopyrimidine derivative: Crystals are obtained by heating an aqueous suspension of 2-(3,4-dichlorobenzyl)-5-methyl-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidine-6-carboxylic acid. Novel crystals are obtained by adjusting the heating temperature and/or duration.... Agent: Aska Pharmaceutical Co., Ltd.

20130123280 - A2b adenosine receptor antagonists: Disclosed are novel compounds that are A2B adenosine receptor antagonists, useful for treating various disease states, including asthma and diarrhea.... Agent: Gilead Sciences, Inc.

20130123281 - Compositions and methods for inhibition of tbl-1 binding to disease-associated molecules: Compositions and methods which modulate diseases and disorders related to transducin β-like protein 1 (TBL1) activity, including but not limited to cancer, inflammation, and bone related diseases.... Agent: Beta Cat Pharmaceuticals, LLC

20130123282 - Solid state forms of linagliptin: The present invention provides solid state forms of Linagliptin, processes for preparing the solid state forms, and pharmaceutical compositions thereof.... Agent:

20130123283 - Methods and compostions for treating pain: The present application relates to compounds and methods for treating pain, incontinence and other conditions.... Agent:

20130123284 - Heterocyclic compounds useful for kinase inhibition: Provided herein are compounds useful for kinase inhibition.... Agent: Amitech Therapeutic Solutions Inc

20130123285 - Compositions and methods for targeting a3g:rna complexes: The present invention provides an assay for screening any agent that modulates the ability of A3G to bind with RNA. The invention provides an agent identified by high throughput screening methods and methods of treatment using the identified agent as a means of inhibiting HIV infection and reducing the emergence... Agent: University Of Rochester

20130123286 - Novel fused heterocyclic derivatives useful as c-met tyrosine kinase inhibitors: Certain novel fused quinazoline derivatives of formula (I) as c-Met inhibitors, their synthesis and their uses for treating a c-Met mediated disorder. Methods for treating a c-Met-mediated disorder are also disclosed in the invention.... Agent:

20130123287 - Control agent for soft rot and control method for the same: Providing a novel control agent for soft rot and a novel control method for the same. A compound having no antibacterial activity against Erwinia carotovora but having a control activity against fungi on soil surface, specifically containing, as the active ingredient, a fungicide comprising any of a strobilurin compound such... Agent: Ishihara Sangyo Kaisha, Ltd.

20130123288 - Polysubstituted derivatives of 2-heteroaryl-6-phenylimidazo[1,2-a]pyridines, and preparation and therapeutic use thereof: o

20130123289 - Certain amino-pyrimidines, compositions thereof, and methods for their use:

20130123290 - Pyrimidylaminobenzamide derivatives for treatment of neurofibromatosis: The present invention relates to the use of pyrimidylaminobenzamide derivatives for the preparation of a drug for the treatment of non-cancerous, benign brain tumors, especially for the curative and/or prophylactic treatment of NF, and to a method of treating non-cancerous, benign brain tumors, especially for the curative and/or prophylactic treatment... Agent: Novartis Ag

20130123291 - Benzodioxole or benzodioxepine heterocyclic compounds as phosphodiesterase inhibitors: Compounds of the general formula (I) wherein each of m and n is independently 0 or 1; R1 and R2, together with the carbon atom to which they are attached, form a heterocyclic ring comprising one or two heteroatoms selected from oxygen, sulfur, —S(O)— and —S(0)2-; R3 is —CHF2, —CF3,... Agent: Leo Pharma A/s

20130123294 - Formulations containing nalbuphine and uses thereof: Immediate release, oral, pharmaceutical formulation including nalbuphine or a pharmaceutically acceptable salt thereof, and at least one hydrophilic granulation carrier, one hydrophilic binder and one lubricant.... Agent: Debregeas Et Associes Pharma

20130123293 - Opioid-containing oral pharmaceutical compositions and methods: The present invention provides sustained-release oral pharmaceutical compositions and methods of use. The sustained-release oral pharmaceutical compositions include an opioid (including salts thereof) and a salt of a non-steroidal anti-inflammatory drug (NSAID).... Agent: Upsher-smith Laboratories, Inc.

20130123292 - Transdermally deliverable opioid prodrugs, abuse-resistant compositions and methods of using opioid prodrugs: Described herein are opioid prodrugs, methods of making opioid prodrugs, formulations comprising opioid prodrugs, and methods of using opioid prodrugs. One embodiment described herein relates to the transdermal administration of a buprenorphine prodrug in an abuse-resistant formulation for treating and preventing diseases and/or disorders.... Agent: Alltranz Inc.

20130123295 - Treatment of neuropathic pain with n-methyl-d-aspartate (nmda) receptor antagonists: Central neuropathic pain is treated with an analgesic composition that consists essentially of an N-methyl-D-aspartate (NMDA) receptor antagonist. In one embodiment, the invention includes chronic administration of the (NMDA) receptor antagonist. In another embodiment, the invention is use of an NMDA receptor antagonist or component thereof for the manufacture of... Agent: Analgesic Neuropharmaceuticals, LLC

20130123296 - Lonidamine analogues for fertility management: Fertility management can include: administering to the subject one or more doses of a compound according to Formula I so as to reduce fertility in the subject. Fertility management can also include administering an effective amount of the compound to: impair Sertoli cell function in a male subject; inhibit spermatogenesis... Agent: The University Of Kansas

20130123297 - Pharmaceutical composition for preventing or treating osteoporosis or obesity comprising phenyltetrazole derivative: r

20130123298 - Pharmaceutical composition for the prevention of perioperative arterial hypotension in humans: Pharmaceutical composition for the prevention of perioperative arterial hypotension in humans comprising noradrenaline for intravenous administration.... Agent: Laboratoire Aguettant

20130123299 - Compounds and methods for treatment of systemic lupus erythematosus: Small molecule compounds are provided for treating lupus as are methods of treating lupus using these compounds.... Agent: The Feinstein Institute For Medical Research

20130123300 - Urea compounds and use thereof for inhibiting apoptosis: A compound of Formula I, or an isomer, pharmaceutically acceptable salt or solvate thereof, is provided. Also, a composition containing a compound of Formula I, or an isomer, pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier, excipient or diluents, is provided. Further, use of a compound of... Agent: Chinese Pla General Hospital

20130123301 - Crystalline salts of quinoline compounds and methods for preparing them: c

20130123303 - Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions: The present invention relates to a method for treating skin diseases and skin conditions in a patient in need thereof which comprises of administering a therapeutically effective amount of a pharmaceutical composition comprising a therapeutically effective amount of 7-(1H-Imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline, or its individual enantiomers or the tautomers thereof, or a pharmaceutically... Agent: Allergan, Inc.

20130123302 - Process for the preparation of 2-(cyclohexylmethyl)-n--1,2,3,4-tetrahydroisoquinoline-7-sulfonamide: Industrially applicable process for preparing 2-(cyclohexylmethyl)-N-{2-[(2S)-1-methylpyrrolidin-2-yl]ethyl}-1,2,3,4-tetrahydroisoquinoline-7-sulfonamide, and salts thereof.... Agent:

20130123304 - Pyridine non-classical cannabinoid compounds and related methods of use: d

20130123305 - Fungicide hydroximoyl-tetrazole derivatives:

20130123306 - Inhibition of mitogen-activated protein kinases in cardiovascular disease: The present invention relates to methods for inhibiting subacute thrombosis and/or intimal hyperplasia following an interventional vascular procedure by contacting a blood vessel or a synthetic material with a mitogen-activated protein kinase (MAPK) pathway inhibitor. The present invention further relates to vascular devices comprising a MAPK pathway inhibitor.... Agent: New York University

20130123307 - Method to control insects resistant to common insecticides: N-Substituted sulfoximines are effective at controlling insects resistant to common insecticides.... Agent: Dow Agrosciences LLC

20130123308 - Long-lasting surface anti-microbial and method of application: A method for trapping, and neutralizing or killing microorganisms on a surface includes applying a barrier-forming composition that comprises an antimicrobial agent onto an inanimate surface, forming a barrier layer on the inanimate surface, in the barrier, trapping and killing microorganisms encountered on the surface and encountered from the environment... Agent: Oasis Consumer Healthcare, LLC

20130123309 - Method for reducing microbial load for individuals with elevated risk conditions: A method for reducing risk of infection from microorganisms for certain elevated-risk individuals, includes: administering a barrier-forming composition in a therapeutically effective amount to a surface, the surface comprising a mucosa, or a mucosal or skin lesion of an individual. The individual has an elevated risk condition selected from: an... Agent: Oasis Consumer Healthcare LLC

20130123310 - Modulators of sperm hypermobility and uses thereof: The invention provides novel compositions and compounds that inhibit CatSper channel activity, that preferentially inhibits sperm hyperactivity over sperm motility, or both. The compounds of the invention are useful as contraceptive agents that may be adminstered to males, females, or concurrently to both sexual partners. The invention further provides methods... Agent: Hydra Biosciences, Inc.

20130123311 - Modulators of pharmacokinetic properties of therapeutics: e

20130123312 - Compositions and methods of using r(+) pramipexole: Pharmaceutical compositions of R(+) pramipexole and methods of using such compositions for the treatment or prevention of diseases associated with or related to mitochondrial dysfunction or increased oxidative stress are disclosed.... Agent: Knopp Neurosciences Inc.

20130123313 - Benzofuranone compound and pharmaceutical composition containing same: a

20130123314 - Method for improving cartilage repair and/or preventing cartilage degeneration in a joint: The invention is in the field of methods for medical treatment. It provides an improved method for repairing damaged cartilage and/or preventing cartilage degeneration in tissue, in particular in a joint by administering a pharmaceutically active agent directly into the fat pad of a joint. The pharmaceutically active agent is... Agent: Maastricht University

20130123315 - Substituted imidazolones, compositions containing such compounds and methods of use: The present invention relates to compounds of the general structure shown in Formula (A): (A): and includes pharmaceutically acceptable salts, solvates, esters, prodrugs, tautomers, and isomers of said compounds. Pharmaceutical compositions and methods of treatment are also included.... Agent:

20130123317 - 2-((r)-2-methylpyrrolidin-2-yl)-1h-benzimidazole-4-carboxamide crystalline form 1: 2-((R)-2-Methylpyrrolidin-2-yl)-1H-benzimidazole-4-carboxamide Crystalline Form 1, ways to make it, compositions comprising it and made using it, and methods of treating patients having disease using it are disclosed.... Agent: Abbvie Inc.

20130123316 - Bendamustine pharmaceutical compositions: The present invention provides pharmaceutical formulations of lyophilized bendamustine suitable for pharmaceutical use. The present invention further provides methods of producing lyophilized bendamustine. The pharmaceutical formulations can be used for any disease that is sensitive to treatment with bendamustine, such as neoplastic diseases.... Agent:

20130123318 - Anti-fungal formulation: Provided herein are compositions and formulations comprising an antifungal agent. Pharmaceutical compositions comprising luliconazole in an amount effective for the treatment of onychomycosis are provided. Also provided are methods for treating dermatomycoses and onychomycosis using the compositions and formulations.... Agent: Topica Pharmaceuticals

20130123319 - Medthod of treating a systemic inflammatory disorder and damaged internal tissues: o

20130123320 - Topical composition for pain relief: Described is a topically applied composition relief of pain. Also described are methods of preparing the composition and methods of using the composition to relieve pain.... Agent:

20130123322 - Benzocycloalkenes as antifungal agents: The present invention relates to fungicidal benzocycloalkene carboxamides or their thiocarboxamide derivatives of formula (I), their process of preparation and intermediate compounds for their preparation, their use as fungicides, particularly in the form of fungicidal compositions and methods for the control of phytopathogenic fungi of plants using these compounds or... Agent:

20130123323 - Fungicidal pyrazoles: Also disclosed are compositions containing the compounds of Formula 1 and methods for controlling plant disease caused by a fungal pathogen comprising applying an effective amount of a compound or a composition of the invention.... Agent: E I Du Pont De Nemours And Company

20130123321 - Plant disease control composition and its use: A plant disease control composition comprising a carboxamide compound represented by following formula (I), wherein R1 represents a hydrogen atom or a methyl group, and R2 represents a methyl group, a difluoromethyl group or a trifluoromethyl group, and fludioxonil is provided by this invention, and this composition has an excellent... Agent: Sumitomo Chemical Company, Limited

20130123324 - Crystalline (1r, 4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine: Crystalline forms of (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine, pharmaceutical compositions and medicaments comprising these crystalline modifications, the use of these modifications as well as a process for the enrichment of such crystalline modifications.... Agent: Gruenenthal Gmbh

20130123325 - Use of boceprevir and related compounds in atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases: The present invention relates to a compound of the formula I for use in the treatment of atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases.... Agent:

20130123326 - Allosteric binding compounds: The present invention relates to allosteric binding compounds of formula (I), especially for the treatment of CNS disorders, together with pharmaceutical compositions and methods of treatment including these compounds.... Agent: Aarhus Universitet

20130123351 - High throughput fabrication of nanoparticles: This application provides a high throughput method of making nanoparticles that utilizes plates comprising wells (e.g., 96-well plates).... Agent: Bind Biosciences, Inc.

20130123352 - Xanthanodien for the treatment of cancer: The present invention relates to a method for the treatment or prophylaxis of a disease associated with hyperproliferative cellular division, comprising administering to a subject in need thereof a therapeutically effective dosage of the pharmaceutical composition comprising xanthanodien, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.... Agent:

20130123353 - Dronedarone solid dispersion and preparation method thereof: A dronedarone solid dispersion and preparation method thereof are disclosed. The solid dispersion is composed of active ingredient dronedarone or its pharmaceutically acceptable salt and a carrier material, wherein the carrier material is povidone, copovidone, hydroxypropyl cellulose, or a mixture thereof.... Agent: Jiangsu Hengrui Medicine Co., Ltd.

20130123354 - Soluble guanylate cyclase (sgc) modulators for treatment of lipid related disorders: Disclosed herein are novel compositions and methods for treating or preventing a variety of disorders and conditions associated with lipid metabolism. The methods generally include administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition comprising one or more sGC modulators alone or in combination... Agent: Ironwood Pharmaceuticals, Inc.

20130123355 - Fatty acids and metal ions compositions and uses thereof: Compositions comprising various fatty acids and their variants such as DHA, DHA-lysoPC, and EPA combined with neuro-therapeutic metal ions such as magnesium (Mg), zinc (Zn) or lithium (Li), capable of traversing the blood-brain barrier (“BBB), and blood nerve barrier (“BNB”) and methods of use of such compositions to provide therapeutic... Agent:

20130123356 - Modulator: The present invention relates to a compound of formula (I), or a pharmaceutically acceptable salt thereof,... Agent: University College London

20130123357 - Methods for providing enhanced resveratrol activity using 4-acetoxy-resveratrol: The present invention relates to a method of providing enhanced resveratrol activity comprising: administering a therapeutically effective amount of 4-acetoxy-resveratrol for the treatment of and preventing physiological and pathophysiological conditions mediated by (1) sirtuins, (2) estrogen and anti-estrogen hormone actions and (3) chemical interventions important for male and female health,... Agent: Brigham Young University

20130123358 - Metabolic benefits to butyrate as a chronic diet supplement: Sodium butyrate was chronically administrated through diet supplementation at 5% w/w in a high fat diet. Supplementation of butyrate prevented development of insulin resistance and obesity in C57BL/6J mice on a high fat diet, and in mice fed on a regular diet of tributyrin. Fasting blood glucose, insulin, and insulin... Agent:

20130123359 - Five and fifteen carbon fatty acids for treating metabolic disorders and as nutritional supplements: According to the present invention, acquired metabolic derangements or fatty acid disorders in humans that are manifested by a deficiency in at least one enzyme involved in fatty acid metabolism are treated with a five carbon or a fifteen carbon fatty acid source. Rapid nutritional supplementation can also be provided... Agent: Baylor Research Institute

20130123360 - Methods and uses relating to the identification of compound associated with bacterial infection: The present invention relates to a method of identifying a compound useful for the treating, reducing or preventing pathogenic infection caused by a microorganism and to the use of the PqsD protein or a functional fragment or variant thereof for the identification of a compound having said effect.... Agent: Sanofi-aventis Deutschland Gmbh

20130123361 - High arachidonic acid producing strains of yarrowia lipolytica: Engineered strains of the oleaginous yeast Yarrowia lipolytica capable of producing greater than 10% arachidonic acid (ARA, an ω-6 polyunsaturated fatty acid) in the total oil fraction are described. These strains comprise various chimeric genes expressing heterologous desaturases, elongases and acyltransferases, and optionally comprise various native desaturase and acyltransferase knockouts... Agent: E I Du Pont De Nemours And Company

20130123363 - Medicinal agent for prevention and/or treatment of hepatocellular carcinoma: The present invention relates to provision of a pharmaceutical agent useful for the prevention and treatment of hepatocellular carcinoma, and the pharmaceutical agent for the prevention and/or treatment of hepatocellular carcinoma contains an acyclic retinoid, a salt thereof, or a solvate of any of these, in combination with a branched-chain... Agent: Kowa Co., Ltd.

20130123362 - Type a gelatin capsule containing pufa in free acid form: A pharmaceutical formulation comprising at least one omega-3 polyunsaturated fatty acid in free acid form or a pharmacologically acceptable derivative thereof is contained in a soft gelatin capsule characterised in that the capsule comprises gelatin extracted by an extraction process comprising acid pre-treatment of a collagen source. One advantage of... Agent:

20130123364 - N6-(1-iminoethyl)-l-lysine for regeneration of alveoli in lungs: The present invention describes the use of N6-(1-iminoethyl)-L-lysine for the manufacture of a medicament for the treatment of pulmonary alveolar damage or destruction in mammals, including in humans.... Agent:

20130123365 - Use of fts and analogs to treat non-autoimmune-allergic and non-allergic inflammatory conditions: Disclosed are methods of treating a mammalian subject afflicted with a non-autoimmune inflammatory condition, comprising administering to the subject a pharmaceutical composition comprising an effective amount of S-farnesylthiosalicylic acid (FTS) or a structural analog thereof, and compositions useful in the practice of the methods.... Agent: Ramot At Tel-aviv University Ltd.

20130123366 - Therapeutic agents for the treatment of lymphoid malignancies: Methods—for treatment and prevention of lymphoid malignancies, including, but not limited to acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), B-cell lymphoma, Acute Myeloid leukemia (AML), and mantle cell lymphoma (MCL). The methods include administration of a therapeutically effective amount of FTY720 (2-Amino-2-[2-(4-octylphenyl)ethyl]propane 1,3-diol hydrochloride) or a derivative, pharmaceutically acceptable... Agent: The Ohio State University Research Foundation

20130123367 - Vinylogous chalcone derivatives and their medical use: The present invention relates to vinylogous chalcone derivatives, in particular the compounds of formula (I) as described and defined herein, pharmaceutical compositions comprising these compounds, and their medical use, including their use in the treatment or prevention of cancer, in particular malignant hematological diseases/disorders.... Agent: Medizinische Universitat Wien

20130123368 - Methods of reducing 15-f2t-isop levels in mammals: Methods of reducing 15-F2t-IsoP levels in mammalian subjects are disclosed herein. In addition, methods of reducing or preventing oxidative stress and treating or preventing related diseases are disclosed.... Agent: Bioactives, Inc.

20130123369 - Composition having biocide activity for aqueous preparations: The present invention refers to a process for bacterial stabilizing aqueous preparations like e.g. calcium carbonate slurries and a composition which can be used for the biocidal treatment of such aqueous preparations.... Agent:

20130123370 - Compositions and methods for treating alzheimer's disease and related disorders and promoting a healthy nervous system: Methods of inhibiting the onset and progression of Alzheimer's disease (AD), mild cognitive impairment (MCI), and related neurodegenerative disorders involving amyloidosis are provided. The methods involve administering a composition comprising a therapeutically effective amount of D-pinitol to individuals who are at risk of developing the disease or have one or... Agent: Mount Sinai School Of Medicine

20130123371 - Anisotropic hydrogels: Anisotropic hydrogels including poly(vinyl alcohol) and which have physical cross-links so as to form materials which exhibit anisotropic mechanical properties characteristic of soft biological tissues wherein the anisotropic hydrogel may be used for tissue reconstruction and/or replacement including vessels, arteries, valve components, cartilage, ligaments, skin, and other medical uses such... Agent: The University Of Western Ontario

20130123372 - Emulsions containing polymeric cationic emulsifiers, substance and process: The present invention is directed to stable emulsions comprising oils and a polymeric cationic emulsifier, the process to obtain said emulsions and the use of said emulsions.... Agent: Basf Se

20130123373 - Use of polyether-based and vinyl monomer-based copolymers as binders for dosing forms comprising solid active ingredients: e

20130123374 - Process for modifying the properties of citrus pulp: A process is disclosed for modifying citrus fiber. Citrus fiber is obtained having a c* close packing concentration value of less than 3.8 w %, anhydrous basis. The citrus fiber can have a viscosity of at least 1000 mPa·s, wherein said citrus fiber is dispersed in standardized water at a... Agent: Cargill Incorporated

20130123375 - Organogel compositions comprising alkylated benzimidazolones: Disclosed is a composition comprising an organogel which comprises: (a) an alkylated benzimidazolone compound; and (b) an organic liquid.... Agent: Xerox Corporation

20130123376 - Process for producing siloxane copolymers with urethane-sulphonamido linking groups: Readily emulsifyable silicone copolymers containing urethanesulfonamido linking groups are prepared by reacting a hydroxyl-functional organic polymer with a halo- or pseudohalo-sulfonyl isocyanate, and then reacting the halo- or pseudohalo-sulfonyl product with an organopolysiloxane bearing aminoalkyl groups, preferably in stoichiometric excess.... Agent: Wacker Chemie Ag

20130116166 - Biomarkers for idiopathic pulmonary fibrosis: Biomarkers, kits, and diagnostic and treatment methods for idiopathic pulmonary fibrosis are provided.... Agent:

20130116165 - Light-activated fusion proteins and uses therefor: The invention, in some aspects relates to synthetic, light-activated fusion proteins and their encoding polynucleotide molecules. In some aspects the invention additionally includes expression of the light-activated fusion proteins in cells and their use in methods such as therapeutic methods and candidate compound screening methods.... Agent: Massachusetts Institute Of Technology

20130116167 - Anti-mart-1 t cell receptors and related materials and methods of use: The invention provides a chimeric T cell receptor (TCR) comprising a variable region of a human TCR and a constant region comprising at least an extracellular domain of a constant region of a non-human TCR, as well as functional variants thereof. The invention also provides polypeptides and proteins related to... Agent: The United States Of America, As Represented By The Secretary, Department Of Health & Human Servic

20130116168 - Pea protein peptides with anti helicobacter pylori activity: The invention relates to a composition comprising pea protein hydrolysate for the treatment and/or prevention of infection by gastrointestinal pathogens, in particular Helicobacter pylori and/or a disease associated with infection by said gastrointestinal pathogen in mammals.... Agent:

20130116169 - Inhibitors of serine proteases, particularly hcv ns3-ns4a protease: The present invention relates to compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these... Agent: Vertex Pharmaceuticals Incorporated

20130116170 - Control of coleopteran insect pests: Improved compositions and methods for controlling coleopteran pests are disclosed. In particular, novel combinations of insecticidal proteins having improved toxicity to coleopteran insect pests such as corn rootworm are provided. Further, a method of killing or controlling coleopteran insect pests using the compositions of the invention is disclosed.... Agent: Syngenta Participations Ag

20130116171 - Methods for treating metabolic disorders using fgf: The method provides methods and compositions for treating metabolic disorders such as impaired glucose tolerance, elevated blood glucose, insulin resistance, dyslipidaemia, obesity, and fatty liver.... Agent: Salk Institute For Biological Studies

20130116173 - Glucagon analogs exhibiting gip receptor activity: Provided herein are glucagon analogs which exhibit potent activity at the GIP receptor, and, as such are contemplated for use in treating diabetes and obesity. In exemplary embodiments, the glucagon analog of the present disclosures exhibit an EC50 at the GIP receptor which is within the nanomolar or picomolar range.... Agent: Indiana University Research And Technology Corporation

20130116172 - Glucagon superfamily peptides exhbiting g protein coupled receptor activity: Provided herein are glucagon superfamily peptides conjugated with GPCR ligands that are capable of acting at a G protein-coupled receptor. Also provided herein are pharmaceutical compositions and kits of the conjugates of the invention. Further provided herein are methods of treating a disease, e.g., a metabolic disorder, such as diabetes... Agent: Marcadia Biotech, Inc.

20130116174 - Compositions and methods for increasing poultry hatchability and early performance: Compositions and methods of improving poultry hatch health are provided herein. Poultry hatch health and hatchability may be improved by administering compositions in ovo prior to hatch. The compositions include iodinated tyrosine-containing proteins, suitably iodinated casein, and carbohydrates.... Agent: The Board Of Trustees Of The University Of Arkansas

20130116175 - Reversible pegylated drugs: Reversible pegylated drugs are provided by derivatization of free functional groups of the drug selected from amino, hydroxyl, mercapto, phosphate and/or carboxyl with groups sensitive to mild basic conditions such as 9-fluorenylmethoxycarbonyl (Fmoc) or 2-sulfo-9-fluorenylmethoxycarbonyl (FMS), to which group a PEG moiety is attached. In these pegylated drugs, the PEG... Agent: Yeda Research And Development Co., Ltd.

20130116176 - Derivatisation of erythropoietin (epo): The present invention relates to a compound which is a polysaccharide derivative of EPO, or of an EPO like protein, wherein the polysaccharide is anionic and comprises between 2 and 200 saccharide units. The present invention also relates to pharmaceutical compositions comprising the novel compounds, and methods for making the... Agent: Lipoxen Technologies Limited

20130116177 - Use of aromatase inhibitors for synchronizing ovulation, inducing superovulation or double ovulation and improving twinning and fertility in a mammal: Described herein are methods for synchronizing ovulation in a herd, inducing superovulation in a single animal, and improving frequency of successful implantation and development of fertilized ova.... Agent: University Of Saskatchewan

20130116178 - Pharmaceutical compositions comprising polyethylene glycol having a molecular weight of less than 600 daltons: A liquid pharmaceutical composition comprising a biodegradable polymer, polyethylene glycol having a molecular weight of less than 600 Daltons, a pharmaceutically active agent and less than 0.5% of an biologically acceptable organic solvent.... Agent: Novartis Ag

20130116179 - Pharmaceutical composition for use in the treatment of a neurodegenerative disease: The present invention refers to a pharmaceutical composition for use in the treatment of a neurodegenerative disease.... Agent: Sanofi-aventis Deutschland Gmbh

20130116180 - Parathyroid hormone analogs and uses thereof: Disclosed are two PTH analog ligands, SP-PTH-AAK and Aib-SP-PTH-AAK, that have long-acting activity at the PTH receptor, as demonstrated both in vitro and in vivo. These polypeptides are thus particularly useful in the treatment of diseases, such as hypoparathyroidism, in which long-acting activity is desired. The method of making the... Agent: The General Hospital Corporation

20130116181 - Method of treating dyspnea associated with acute heart failure: The disclosure pertains to methods of reducing decompensation through acute intervention including in subjects afflicted with acute decompensated heart failure. Particularly, the disclosure provides methods for treating acute cardiac decompensation by administering a pharmaceutically effective amount of relaxin.... Agent: Novartis Ag

20130116182 - Factor viii b cell epitope variants having reduced immunogenicity: Provided herein are methods and compositions for preventing or reducing an initial immune response to factor VIII in patients suffering from hemophilia A, and for reducing the intensity of the immune response in patients having pre-formed inhibitor antibodies against factor VIII.... Agent:

20130116183 - Peptides that inhibit angiotensin converting enzyme and peptides with antioxidant activity purified from ovotransferrin and methods of producing and using the same: Described herein are methods of identifying and releasing bioactive peptides from ovotransferrin The method involves (a) contacting ovotransferrin with a reducing agent, a sonication step, a high pressure processing step, a heating step, a fermentation step, or any combination thereof, and (b) contacting the ovotransferrin after step (a) with a... Agent:

20130116185 - Phosphatidylinositol 3-kinases activity regulator including the fifth zinc finger domain of fog2: The present invention relates to a phosphatidylinositol 3-kinases activity regulator which include the fifth zinc finger domain of FOG2 and which, more specifically, can induce cancer cells to die due to the inclusion of the fifth zinc finger domain of FOG2. Since the death of cancer cells is induced by... Agent: Snu R&db Foundation

20130116184 - Rfamide-related peptides and methods thereof: Provided herein methods and compositions directed to RFRP-1 polypeptides for modulating cardiac contractile function, for preventing and/or treating cardiac disorders.... Agent: The Regents Of The University Of Michigan

20130116187 - Artificial cartilage and its production method: An artificial cartilage comprising 15-95% by mass of collagen, 4.9-70% by mass of proteoglycan, and 0.1-20% by mass of hyaluronic acid.... Agent: Hoya Corporation

20130116186 - Lubricin injections to maintain cartilage health: Disclosed are novel methods of maintaining articular cartilage health in an atraumatic, non-diseased joint of a mammal, either human or non-human. The methods involve injecting into the joint capsule of the mammal an amount of a lubricin polypeptide to prevent shear-induced chondrocyte apoptosis and to maintain a lubricin-expressing phenotype of... Agent: Rhode Island Hospital, A Lifespan Partner

20130116190 - Hyaluronic acid-collagen matrices for tissue engineering: Hydrogels comprising a macromolecular matrix including a crosslinked combination of hyaluronic acid and collagen, are provided for tissue engineering applications.... Agent: Allergan, Inc.

20130116188 - Implantable hyaluronic acid/collagen compositions: Hyaluronic acid and collagen may be crosslinked in aqueous solution as described herein. The crosslinked macromolecular matrices obtained in this process may be used as a hydrogel for implants and fillers for human aesthetic and therapeutic products.... Agent: Allergan, Inc.

20130116189 - Retinol-modified collagen, method for producing same, and external composition for skin containing same: Disclosed is a compound which exhibits a higher effect of preventing wrinkle formation, a higher effect of improving wrinkles, a higher effect of making the skin beautiful, and a higher effect of improving skin quality than conventional retinol and retinol derivatives in a sustained manner. Further disclosed are a method... Agent: National University Corporation Nara Institute Of Science And Technology Of Nara, Japan

20130116191 - Transport protein which is used to introduce chemical compounds into nerve cells: The invention relates to a transport protein which can be obtained by modifying the heavy chain of the neurotoxin formed by Clostridium botulinum. The protein binds specifically to nerve cells with a higher affinity as the native neurotoxin. The invention also relates to a method for the production of transport... Agent: Toxogen Gmbh

20130116192 - N-(aminoacyl)-amino compound: Z is a straight chain or branched alkylene, which may contain up to 3 carbon atoms. and R5 is nitrogen or sulphur or oxygen or salts thereof and ester compounds, characterised in that A is an ester or amino acid or alternatively sodium or a potassium salt of arginate and/or... Agent:

20130116193 - Use of the pat nonapeptide in treating and preventing neurodegenerative diseases: The invention relates to the use of the PAT nonapeptide in the manufacture of a drug for preventing or treating a neurodegenerative disease such as Alzheimer's disease. The parenteral route of administration is preferable, including the subcutaneous, intraperitoneal, intravenous or intranasal routes. The invention also relates to an injectable formulation... Agent: Cll Pharma

20130116194 - Cosmetic composition for restoring lipidic layer of the stratum corneum in orthorhombic: The present invention refers to a cosmetic composition of the oil-in-glycol type comprising (a) at least one sucrose non-ionic surfactant or derivatives thereof, (b) at least one fatty alcohol, (c) at least one glycol and (d) at least one ingredient selected from aminoacid and/or peptide, as well as associated uses,... Agent: Isp Investments Inc.

20130116195 - Binding ligand linked drug delivery conjugates of tubulysins: Described herein are compounds, pharmaceutical compositions, and methods for treating pathogenic cell populations. Kits including the compounds or pharmaceutical compositions are described. The compounds described herein include conjugates of tubulysins and folates. The conjugates also include a releasable bivalent linker.... Agent:

20130116196 - Muscle fatigue substance cytokines and methods of inhibiting tumor growth therewith: Compositions and methods for inhibiting tumor growth and tumor cell proliferation are provided. In general, the cytokines useful with the present invention are selected from the group consisting of LIX (or CXCL5), TIMP-1, and sICAM.... Agent: Translational Genomics Research Institute

20130116197 - Modified binding proteins inhibiting the vegf-a receptor interaction: The present invention relates to binding proteins specific for VEGF-A, in particular to recombinant binding proteins comprising a polyethylene glycol moiety and a binding domain, which inhibits VEGF-Axxx binding to VEGFR-2. Examples of such recombinant binding proteins are proteins which comprise an ankyrin repeat domain with the desired binding specificity,... Agent:

20130116198 - Compositions for regenerating defective or absent myocardium: Compositions of the invention for regenerating defective or absent myocardium comprise an emulsified or injectable extracellular matrix composition. The composition may also include an extracellular matrix scaffold component of any formulation, and further include added cells, proteins, or other components to optimize the regenerative process and restore cardiac function.... Agent:

20130116199 - Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders: The invention provides novel guanylate cyclase-C agonist peptides and their use in the treatment of human diseases including gastrointestinal disorders, inflammation or cancer (e.g., a gastrointestinal cancer). The peptides can be administered either alone or in combination with an inhibitor of cGMP-dependent phosphodiesterase. The gastrointestinal disorder may be classified as... Agent: Synergy Pharmaceuticals Inc.

20130116200 - Treatment of vascular complications of diabetes: A peptide consisting of 7-17 amino acids and including the adjacent hexamer TX1EX2X3E, where X1, X2 and X3 can be any natural or non natural amino acid, wherein the peptide does not exhibit TNF-receptor-binding activity and is cyclic, for the treatment or prevention of vascular complications in diabetes patients.... Agent: Apeptico Forschung Und Entwicklung Gmbh

20130116201 - Use of peptides as transporters intended for the internalization of molecules of interest into target cells: The method pertains to a peptide including the amino acid sequence SEQ ID NO: 1, or a peptide including an amino acid sequence having 93%, in particular 95%, particularly 98% sequence identity homology with the sequence SEQ ID NO: 1, in order to obtain a transporter intended for the internalization... Agent: Universite Joseph Fourier

20130116202 - Ngna compositions and methods of use: The present invention relates to the field of viral disorders, and in particular to the use of natural compounds to inhibit viruses and viral infection. Compositions comprising NGNA are provided for treating or preventing viral infections, such as those causing the common cold.... Agent: Life Science Nutrition As

20130116203 - Isothiocynates and glucosinolate compounds and anti-tumor compositions containing same: The present invention provides glucosinolate and isothiocyanate compounds and related methods for synthesizing these compounds and analogs. In certain embodiments, these glucosinolate and isothiocyanate compounds are useful and chemopreventive and or chemotherapeutic agents.... Agent:

20130116204 - (methylsulfonyl) ethyl benzene isoindoline derivatives and their pharmaceutical uses: Provided are (methylsulfonyl)ethyl benzene isoindoline compounds, and pharmaceutically acceptable salts, solvates, or stereoisomers thereof. Methods of use and pharmaceutical compositions of these compounds are also disclosed.... Agent: Celgene Corporation

20130116205 - Composition containing iridoids and uses thereof: Composition containing iridoids such as morroniside and loganin, the use thereof in preparing medicaments for preventing and treating neurologic demyelinating diseases, and the method thereof in treating diseases related to neurologic demyelinating lesions are disclosed by the present application.... Agent: Xuanwu Hospital Of Capital Medical University

20130116208 - Administration of a nedd8-activating enzyme inhibitor and hypomethylating agent: The present disclosure relates to methods for the treatment of cancer in patients in recognized need of such treatment. The methods comprise administering to such a patient an NAE inhibitor or a pharmaceutically acceptable salt thereof, such as ((1S,2S,4R)-4-(4-((1S)-2,3-dihydro-1H-inden-1-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-hydroxycyclopentyl)methyl sulfamate (MLN4924) or {(1S,2S,4R)-4-[(6-{[(1R,2S)-5-chloro-2-methoxy-2,3-dihydro-1H-inden-1-yl]amino}pyrimidin-4-yl)oxy]-2-hydroxycyclopentyl}methyl sulfamate (I-216), and a hypomethylating agent or... Agent: Millennium Pharmaceuticals, Inc.

20130116207 - Compositions and methods for treating cancer: Provided herein are compounds used to inhibit the deamination enzyme responsible for the inactivation of therapeutic compounds, and methods of using them.... Agent: Eisai Inc.

20130116206 - Quinoline derivatives used as pet imaging agents: There is provided compounds of formula (I), wherein R1, R2, X1, X2, and X3 have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful as positron emission tomography (PET) imaging agents, useful in the treatment of diseases in which inhibition of epidermal growth factor receptor tyrosine... Agent: Imperial Innovations Limited

20130116303 - Antagonists of mirna-29 expression and their use in the prevention and treatment of aneurysm: The present invention relates to antagonists of the expression and/or the function of the micro RNA miRNA-29 for use in the prevention and/or treatment of aortic aneurysms. Further disclosed is a method for the identification of miRNA-29 antagonists, a pharmaceutical composition comprising said miRNA-29 antagonists and a method for preventing... Agent: Johann Wolfgang Goethe-universitat Frankfurt Am Main

20130116301 - Antisense modulation of gcgr expression: Provided herein are methods, compounds, and compositions for reducing expression of GCGR mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate metabolic disease, for example, diabetes, or a symptom thereof.... Agent: Isis Pharmaceuticals, Inc.

20130116310 - Antisense oligonucleotides for inducing exon skipping and methods of use thereof: An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 202.... Agent: The University Of Western Australia

20130116308 - Cd36 inhibition to control obesity and insulin sensitivity: The disclosure relates to the therapeutic utility of CD36 antagonists to reduce body weight, inhibit fat accumulation and especially visceral fat accumulation, improve insulin sensitivity, lower blood glucose levels, and treat and prevent metabolic syndrome, pre-diabetes and diabetes, and lower plasma cholesterol levels and decrease fat deposit in the liver.... Agent: Cornell University

20130116299 - Methods and compositions for increasing sensitivity to tyrosine kinase inhibitors: The present invention relates to a method for sensitizing a disease cell expressing the epidermal growth factor receptor (EGFR) to a tyrosine kinase inhibitor selective or specific for EGFR and/or its signalling pathway, the method comprising contacting the cell with a miR-7 miRNA, a precursor or variant thereof, or a... Agent:

20130116305 - Methods and compositions for the inhibition of hiv-1 replication: This invention relates to methods and compositions for the attenuation of HIV-1 replication in human cells, and especially in human macrophages. The invention particularly concerns the use of inhibitors of P21 (CDKNIA) expression to attenuate such replication. The invention particularly concerns the use of antisense P21 oligonucleotides, siRNA and/or 2-cyano-3,12-dioxooleana-1,9-dien28-oic... Agent: The United States Of America, As Represented By Secretary, Department Of Health & Human Services

20130116307 - Novel cyclic cationic lipids and methods of use: The present invention provides compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel cationic lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo. The compositions of the present... Agent: Protiva Biotherapeutics Inc.

20130116309 - Oligomeric compounds for the modulation of hif-1a expression: Oligonucleotides directed against the hypoxia-inducible factor-1α (HIF-1α) gene are provided for modulating the expression of HIF-1α. The compositions comprise oligonucleotides, particularly antisense oligonucleotides, targeted to nucleic acids encoding the HIF-1α. Methods of using these compounds for modulation of HIF-1α expression and for the treatment of diseases associated with the hypoxia-inducible... Agent: Enzon Pharmaceuticals, Inc.

20130116302 - Pharmaceutical composition for the treatment of chlamydial infection: Subject of the present invention is a pharmaceutical composition comprising at least one inhibitor of a microorganism selected from the family Chlamydiaceae.... Agent: Max-planck-gesellschaft Zur Foerderung Der Wissenschaften E.v.

20130116306 - System for delivering nucleic acids for suppressing target gene expression by utilizing endogenous chylomicron: The object of present invention is to provide a system that can deliver in vivo nucleic acids such as an siRNA for suppressing a target gene expression in vivo more safely and efficiently, and to provide an expression-suppressing agent and a pharmaceutical composition utilizing the system. An introduction substance into... Agent: National University Corporation Tokyo Medical And Dental University

20130116304 - Tmem195 encodes for tetrahydrobiopterin-dependent alkylglycerol monooxygenase activity: The present invention relates to the provision of a pharmaceutical composition comprising a nucleic acid molecule encoding a alkylglycerol monooxygenase (TMEM195; glyceryl ether monooxygenase; EC 1.14.16.5). The present invention also provides for a method for producing said alkylglycerol monooxygenase (TMEM195; glyceryl ether monooxygenase; EC 1.14.16.5) polypeptides encoded by said polynucleotides.... Agent:

20130116300 - Treatment of membrane bound transcription factor peptidase, site 1 (mbtps1) related diseases by inhibition of natural antisense transcript to mbtps1: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Membrane Bound Transcription Factor Peptidase, site 1 (MBTPS1), in particular, by targeting natural antisense polynucleotides of Membrane Bound Transcription Factor Peptidase, site 1 (MBTP-S1). The invention also relates to the identification of these antisense oligonucleotides... Agent: Curna, Inc.

20130116311 - Catecholamine enzyme fusions: Provided is a construct comprising (i) a nucleotide sequence which encodes tyrosine hydroxylase (TH), (ii) a nucleotide sequence which encodes GTP-cyclohydrolase I (CH1) and (iii) a nucleotide sequence which encodes Aromatic Amino Acid Dopa Decarboxylase (AADC) wherein the nucleotide sequence encoding TH is linked to the nucleotide sequence encoding CH1... Agent: Oxford Biomedica (uk) Ltd.

20130116209 - Method for selection of chemotherapeutic agents for adenocarcinoma cancer: The subject invention relates to determining the presence and level of hENT1 expression in tumor tissue that is appropriate for gemcitabine therapy, and more importantly, the level of hENT1 expression that signifies that treatment with a gemcitabine derivative is a more appropriate strategy.... Agent: Clovis Oncology, Inc.

20130116210 - Controlled release antimicrobial compositions and methods for the treatment of otic disorders: Disclosed herein are compositions and methods for the treatment of otic diseases or conditions with antimicrobial agent compositions and formulations administered locally to an individual afflicted with an otic disease or condition, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s).... Agent: The Regents Of The University Of California

20130116211 - Novel salts of boswellic acids and selectively enriched boswellic acids and processes for the same: New salts or ion-pair complexes obtained by a reaction between boswellic acids or selectively enriched 3-O-acetyl-11-keto-β-boswellic acid (AKBA) or 11-keto-β-boswellic acid (KBA) compounds obtained through a new improved process, and an organic amine, more particularly with glucosamine. These salts or ion pair complexes are useful in nutraceuticals and in food... Agent:

20130116212 - Oil-based gel-like composition: The oil-based gel-like composition of the present invention comprises 1 to 30% by weight of a gel-forming agent and 70 to 99% by weight of an oil-phase component, the gel-forming agent being obtained by blending polyglycerin having a degree of polymerization of 3 to 20 in an amount of [6.8... Agent: Daicel Corporation

20130116213 - Novel fused pyrimidine derivatives for inhibition of tyrosine kinase activity: The present invention relates to a novel fused pyrimidine derivative having an inhibitory activity for tyrosine kinases, and a pharmaceutical composition for preventing or treating cancers, tumors, inflammatory diseases, autoimmune diseases, or immunologically mediated diseases comprising same as an active ingredient.... Agent: Hanmi Science Co., Ltd.

20130116214 - Heterocyclic ring compound: e

20130116215 - Combination therapies for treating neurological disorders: The invention features novel pharmaceutical combinations useful for the treatment of neurological diseases, specifically neurodegenerative diseases. The novel pharmaceutical combinations of the invention demonstrate additive or synergistic effect in silico and in vivo. The invention also relates to methods of treatment of neurological and neurodegenerative diseases including the pharmaceutical combinations... Agent:

20130116216 - Transglutaminase tg2 inhibitors, pharmaceutical compositions, and methods of use thereof: Certain compounds and pharmaceutically acceptable salts are provided herein. Also provided are pharmaceutical compositions comprising at least one compound or pharmaceutically acceptable salt therein and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain disease states responsive to the inhibition of transglutaminase TG2 activity are described.... Agent:

20130116217 - Neuroprotection and myelin repair using nestorone®: Methods for treating neurodegeneration and/or myelination in patients are disclosed comprising treating the patient with a progestin compound which exerts binding to progesterone receptors and elicits progesterone-receptor-induced biological responses without interacting with the androgen receptor and without inducing androgen or glucocorticoid biological responses at a dosage sufficient to prevent or... Agent: The Population Council, Inc.

20130116219 - Antimicrobial carboline compounds: The invention provides compositions comprising carboline compounds for treating infections such as viral conjunctivitis. The invention also provides methods for treating of other infections, including ocular infections. More particularly, the present invention relates to compositions comprising carboline compounds for the treatment of ocular infections such as viral conjunctivitis, particularly those... Agent: Alcon Research, Ltd.

20130116218 - Methods and compositions of bile acids: Methods and compositions are provided for treating metabolic disorders by modulating bile acid levels. Generally, the methods and compositions can modulate bile acid levels, such as serum bile acid levels, to treat a metabolic disorder. In one embodiment, a method of modulating a bile acid level includes measuring a bile... Agent: The General Hospital Corporation D/b/a Massachusetts General Hospital

20130116220 - Polymeric pheromone formulation and method of use to calm stress-related behavior in mammals over an extended period of time: Pheromone compositions comprising a combination of squalene, linoleic acid and 1-docosanol are described, along with methods of using the pheromone compositions to modify behavior in mammals. The compositions are useful for behavior modification in mammals that exhibit undesirable or harmful stress-related behaviors.... Agent: Sergeant's Pet Care Products, Inc.

20130116221 - Theobromine for increasing hdl-cholesterol: Theobromine for use in the treatment of increasing HDL-cholesterol and/or increasing the ratio HDL-cholesterol:LDL-cholesterol in humans and the use of theobromine for increasing HDL-cholesterol in humans, and/or for increasing the ratio HDL-C/LDL-C, and compositions comprising theobromine.... Agent:

20130116222 - Dermal delivery compositions and methods: A composition for transdermal delivery of a progestin for progestin hormone therapy is disclosed. Also disclosed is a transdermal delivery device comprising the composition. For progestin-only hormone therapy, the composition contains an anti-oxidant and does not contain an estrogen. For therapy involving a progestin and an estrogen, the composition contains... Agent:

20130116223 - Medicinal cosmetic lipoatrophy: Methods relating to local injections of corticosteroids are provided. More specifically intralesional injections of corticosteroids and preferably Triamcinolone and its derivatives are suitable to produce medicaments to be injected in the subcutaneous fat at deep levels to provoke cosmetic lipoatrophy of small fat deposits on the face and body.... Agent:

20130116224 - Method and composition for treatment of tumors: A method for ameliorating tumors which result from high or increased activity of Gli by treating a human subject evidencing tumor growth by treating the subject with a deactivating effective amount of CTC-96 to reduce or inhibit tumor growth.... Agent:

20130116226 - Method for treating esophageal cancer: Methods and compositions for treating gastric and esophageal cancers are disclosed.... Agent: Niiki Pharma Inc.

20130116225 - Method for treating hematological cancers: Methods and compositions for treating hematological cancer are disclosed, including refractory or resistant hematological cancer.... Agent: Niiki Pharma Inc.

20130116227 - Biaryl amide derivative or pharmaceutically acceptable salt thereof: Disclosed is a novel biaryl amide derivative represented by formula (1) and having an affinity for the aldosterone receptor; also disclosed is a pharmaceutically acceptable salt thereof. (In the formula, A is any of the groups represented by formula (a); L is —CONH—, etc.; R1 is a substitutable aminosulfonyl group,... Agent: Dainippon Sumitomo Pharma Co., Ltd.

20130116230 - 3-aminopyrrolidine derivatives as modulators of chemokine receptors: (wherein R1, R2, R3, R4, R5, R6, R7, R8, X, Y and X are as defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of chemokine receptors and more specifically as a modulator of the CCR2 and/or CCR5 receptor. The... Agent: Incyte Corporation

20130116229 - Novel inhibitor compounds of phosphodiesterase type 10a: The present invention relates to compounds which are inhibitors of phosphodiesterase type 10A and to their use for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders... Agent: Abbott Gmbh & Co. Kg

20130116231 - Tyrosine kinase inhibitors: The present invention relates to 1,4-dihydropyridazinone derivatives, that are useful for treating cellular proliferative diseases, for treating disorders associated with MET activity, and for inhibiting the receptor tyrosine kinase MET. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.... Agent: Merck Sharp & Dohme Corp.

20130116232 - Estrogen receptor modulators and uses thereof: Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen... Agent: Aragon Pharmaceuticals, Inc.

20130116228 - Thiazoles and pyrazoles useful as kinase inhibitors: The present invention relates to compounds useful as inhibitors of Aurora protein kinases. The invention also provides pharmaceutically acceptable compositions comprising those compounds and methods of using the compounds and compositions in the treatment of various disease, conditions, and disorders. The invention also provides processes for preparing compounds of the... Agent: Vertex Pharmaceuticals Incorporated

20130116234 - Aryl-quinoline derivatives: wherein R1, R2, R3, R4, R5, R6 and n are as described herein, compositions including the compounds and methods of using the compounds. The present compounds are useful as fatty-acid binding protein (FABP) 4 and/or 5 inhibitors and may be used for the treatment or prophylaxis of lipodystrophy, type 2... Agent: Hoffmann-la Roche Inc.

20130116235 - Heteroaryl pyridone and aza-pyridone compounds: Heteroaryl pyridone and aza-pyridone compounds of Formula I are provided, where one or two of X1, X2, and X3 are N, and including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using... Agent: Genentech, Inc.

20130116233 - Novel inhibitor compounds of phosphodiesterase type 10a: The present invention relates to novel compounds of the formula I which are inhibitors of phosphodiesterase type 10A and to their use for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the... Agent: Abbott Gmbh & Co. Kg

20130116236 - Novel [1,2,3]triazolo[4,5-d]pyrimidine derivatives: e

20130116237 - [6,6] and [6,7]-bicyclic gpr119 g protein-coupled receptor agonists:

20130116238 - Modulators of atp-binding cassette transporters: Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.... Agent: Vertex Pharmaceuticals Incorporated

20130116239 - Ivabradine-containing pharmaceutical composition with modified release: The present invention relates to pharmaceutical compositions with delayed release which contain ivabradine adipate as active substance. The present invention furthermore relates to processes for the preparation of this composition and certain salts of ivabradine.... Agent: Ratiopharm Gnbh

20130116240 - Indole compounds and pharmaceutical use thereof: e

20130116242 - Method of treatment of hormone depletion induced vasomotor: The invention provides a method to effectively wean a woman from hormone therapy for treatment of vasomotor symptoms by reducing the dosage of the hormonal agent to zero, while a non-hormonal drug in an amount, which is therapeutically effective for treating vasomotor symptoms, is administered or initiated and continued for... Agent:

20130116241 - Novel inhibitor compounds of phosphodiesterase type 10a: e

20130116243 - Inhibitors of akt activity: The invention relates to a series of compounds with particular activity as inhibitors of the serine-threonine kinase AKT. Also provided are pharmaceutical compositions comprising same as well as methods for treating cancer.... Agent: Almac Discovery Limited

20130116244 - Pharmaceutical powder compositions: The present invention provides a powder composition for the buccal delivery comprising a drug compound, a muco-adhesive agent and a dispersing agent Suitable compounds drugs include benzodiazepine compounds. Suitable muco-adhesive agents include those selected from (t) esters and salts of alginic acid and (it) hydroxyethyl cellulose. Suitable dispersing agents include... Agent: Aesica Formulation Development Limited

20130116246 - 8-fluorophthalazin-1(2h)-one compounds: 8-Fluorophthalazin-1(2h)-one compounds of Formula II where one or two of X1, X2, and X3 are N, are provided, including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using compounds of Formula II... Agent: Genentech, Inc.

20130116245 - Alkylated piperazine compounds: Alkylated piperazine compounds of Formula I are provided, including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and... Agent: Genentech, Inc.

20130116247 - Ire-1alpha inhibitors: Compounds which directly inhibit IRE-1α activity in vitro, prodrugs, and pharmaceutically acceptable salts there-of. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response or with regulated IRE1-dependent decay (RIDD) and can be used as single agents or in combination therapies.... Agent: Mannkind Corporation

20130116248 - Substituted imidazoquinoline derivatives as kinase inhibitors: The present invention relates to substituted imidazo[4,5-c]quinoline derivatives, the compounds of formula (I), wherein R1, R2, R3, R4, R5, R6 and R7 are as defined in the specification, processes for their preparation, pharmaceutical compositions comprising compounds of formula (I), and their use in the treatment of diseases or disorders mediated... Agent: Piramal Enterprises Limited

20130116250 - Imidazopyridine derivatives, process for preparation thereof and therapeutic use thereof: e

20130116249 - Indolizine derivatives, process for the preparation thereof and therapeutic use thereof:

20130116255 - Combination of brimonidine and timolol for topical ophthalmic use: Disclosed are pharmaceutical compositions comprising brimondine and timolol for topical ophthalmic delivery and a method of treatment comprising administering said composition when indicated for glaucoma and associated conditions such as elevated intraocular pressure in the eyes of humans.... Agent: Allergan, Inc.

20130116254 - Compositions and methods for lowering intraocular pressure: Disclosed herein are compositions for lowering intraocular pressure (IOP) of an eye comprising a combination of the IOP-lowering agents bimatoprost, brimonidine, and timolol. Further disclosed are methods for reducing IOP in the eye of a subject.... Agent: Allergan, Inc.

20130116251 - Novel hsp90 inhibitor: Disclosed is a triazole derivative(s) represented by the general formula (1) below or a pharmacologically acceptable salt(s) thereof. Also disclosed are a prodrug(s) of such a triazole derivative(s) and an HSP90 inhibitor(s) containing any one of them as an active constituent. (1) (In the formula, X represents a halogen atom,... Agent: Nippon Kayaku Kabushiki Kaisha

20130116252 - Novel hsp90 inhibitor: Disclosed is a triazole derivative(s) represented by the general formula (1) below or a pharmacologically acceptable salt(s) thereof. Also disclosed are a prodrug(s) of such a triazole derivative(s) and an HSP90 inhibitor(s) containing any one of them as an active constituent. (1) (In the formula, X represents a halogen atom,... Agent: Nippon Kayaku Kabushiki Kaisha

20130116253 - Novel hsp90 inhibitor: Disclosed is a triazole derivative(s) represented by the general formula (1) below or a pharmacologically acceptable salt(s) thereof. Also disclosed are a prodrug(s) of such a triazole derivative(s) and an HSP90 inhibitor(s) containing any one of them as an active constituent. (1) (In the formula, X represents a halogen atom,... Agent: Nippon Kayaku Kabushiki Kaisha

20130116256 - Hexenone compounds and medical use thereof: The present invention relates to a compound of Formula I, or an isomer, pharmaceutically acceptable salt and solvate thereof; to a composition comprising a compound of Formula I, or an isomer, pharmaceutically acceptable salt and solvate thereof, and a pharmaceutically acceptable carrier, excipient or diluent; and also to use of... Agent: Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.l.a. China

20130116257 - Method for treating a pulmonary hypertension condition: A method for treating a pulmonary hypertension condition such as pulmonary arterial hypertension (PAH) in a subject comprises administering to the subject a therapeutically effective amount of ambrisentan, wherein, at baseline, time from first diagnosis of the condition in the subject is not greater than about 2 years.... Agent: Gilead Colorado, Inc.

20130116258 - Androgen receptor modulators and uses thereof: Described herein are compounds that are androgen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such androgen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon... Agent: Aragon Pharmaceuticals, Inc.

20130116259 - Combination therapy for treating or preventing an inflammatory skin disorder: Methods and compositions for improved treatment and prevention of an inflammatory skin disorder or a sign and/or symptom associated with the skin disorder are described. The methods involve topical application to the skin a combination of a therapeutically effective amount of an α2 adrenergic receptor agonist, such as brimonidine, and... Agent: Galderma Research & Development

20130116260 - Fused heteroaromatic pyrrolidinones as syk inhibitors: and pharmaceutically acceptable salts thereof, wherein G, L1, L2, R1, R2, R3, and R4 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, pharmaceutical compositions containing them, and their use for treating disorders, diseases, and conditions involving the immune system... Agent: Takeda Pharmaceutical Company Limited

20130116261 - Nanoparticles for encapsulation of compounds, the production and uses thereof: The present invention relates to nanoparticles for the encapsulation of compounds, the obtaining and uses thereof. The nanoparticles comprise a zein matrix and a basic amino acid. Said nanoparticles can encapsulate a water-soluble or fat-soluble biologically active compound. It is applicable in the food, pharmaceutical and cosmetic sectors and in... Agent: Centro Nacional De Tecnolog&#xcd A Y Seguridad Alimentaria, Laboratorio Del Ebro

20130116262 - Bicyclic piperazine compounds: Bicyclic piperazine compounds of Formula I are provided, including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and... Agent: Genentech, Inc.

20130116264 - Novel hetaryl (thio)carboxamide compounds for controlling invertebrate pests: The present invention further relates to a method for controlling invertebrate pests, to a method for protecting plant propagation material and/or the plants which grow therefrom, to plant propagation material, comprising at least one hetaryl (thio)carboxamide compound according to the present invention, to a method for treating or protecting an... Agent: Basf Se

20130116263 - Pak inhibitors for the treatment of cell proliferative disorders: Provided herein are PAK inhibitors and methods of utilizing PAK inhibitors for the treatment of cell proliferative disorders and/or CNS disorders.... Agent: Afraxis, Inc.

20130116265 - Compound for inhibiting type 5 phosphodiesterase and preparation method thereof: The present invention discloses a compound of formula (I) and citrate thereof as type 5 phosphodiesterase inhibitor, a preparation method thereof, and a pharmaceutical composition including the compound of formula (I) and citrate thereof. The experimental results of the present invention prove that the compound of formula (I) and citrate... Agent:

20130116266 - Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta: Compounds that inhibit P13Kδ activity, including compounds that selectively inhibit P13Kδ activity, are disclosed. Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (P13Kδ) activity, and methods of treating diseases, such as disorders of immunity and inflammation in which P13Kδ plays a role in leukocyte function, using the compounds also are disclosed.... Agent: Icos Corporation

20130116267 - Role of pi3k p110 delta signaling in retroviral infection and replication: The invention includes compositions and methods for regulating PI3K p110 delta as an anti-retroviral therapy. The invention includes a method of inhibiting p110 delta, a component of PI3K p110 delta signaling pathway, or any combination thereof in a cell as an anti-retroviral therapeutic approach for treating a retroviral infection, for... Agent:

20130116268 - Use of modified pyrimidine compounds to promote stem cell migration and proliferation: Disclosed herein are methods and materials for improving vision. Particularly exemplified herein are pyrimidine compounds that serve to proliferate retinal stem cells.... Agent:

20130116269 - Cyclic n,n'-diarylthioureas and n,n'-diarylureas - androgen receptor antagonists, anticancer agent, method for preparation and use thereof: s

20130116270 - Novel compounds: The invention relates to novel spirocyclic derivatives with affinity for Ca.,2.2 calcium channels and which are capable of interfering with Cav2.2 calcium channels; to processes for their preparation; to pharmaceutical compositions containing them; and to the use of such compounds in therapy for the treatment of pain.... Agent: Convergence Pharmaceuticals Limted

20130116271 - Tacrolimus-containing oil-in-water type creamy composition: The present invention relates to an oil-in-water type creamy composition comprising (A) tacrolimus, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, (B) an oil prepared by mixing (a) a medium-chain fatty acid triglyceride with (b) ethylene glycol salicylate and/or diisopropyl sebacate, (C) an emulsifying agent having a... Agent: Maruho Co., Ltd.

20130116273 - Beta carboline derivatives useful in the treatment of proliferative disorders: The invention provides novel beta-carboline derivatives of formulae (Ia) and (Ib) useful in the treatment of proliferative disorders including cancer, intermediates used in their preparation, processes for preparing the same and uses thereof.... Agent: Facultes Universitaires Notre Dame De La Paix

20130116272 - Heterocyclic fused phenanthrolinone m1 receptor positive allosteric modulators: The present invention is directed to heterocyclic fused phenanthrolinone compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed... Agent:

20130116274 - Therapeutic combinations containing riluzole: Disclosed is a method of treating melanoma in a mammal comprising administering (a) a therapeutically effective amount of an inhibitor of metabotropic glutamate receptor 1 (GRM1); and (b) a therapeutically effective amount of an inhibitor of at least one downstream signaling target of GRM1. Also disclosed are compositions and kits... Agent: Rutgers, The State University Of New Jersey

20130116275 - Inhibitors of hif and angiogenesis: Inhibitors of the Hypoxia Inducible Factor (HIF) and angiogenesis and their methods of use including the treatment of cancer, hypoxia related pathologies, disorders leading to ischemia, for example stroke and ischemic heart disease, and non-cancerous angiogenic diseases are provided.... Agent: Emory University

20130116276 - New use of neferine: The present invention reveals a new use of neferine. Neferine regulates M8 and V1 subtype of transient receptor potential ion channel (TRPM8 and TRPV1), respectively, in mammalians, including humans, and can be used for preparing medicaments for treating disease related to said ion channel (such as hyperalgesia, Parkinson's disease, painful... Agent: Institute Of Chinese Materia Medica, Chinese Academy Of Medical Sciences

20130116277 - Aldo-keto reductase subfamily 1c3 (akr1c3) inhibitors: The present invention relates to a novel class of AKR1C3 inhibitors, to compositions containing them, to methods for their preparation, and to methods of use thereof. The AKR1C3 inhibitors may be useful in the treatment of, for example, prostate cancer, benign prostate hyperplasia (BPH), lung cancer, acne, seborrhea, hirsuitism, baldness,... Agent:

20130116278 - Antimicrobial agents: The invention provides a compound of formula (I): or a salt or prodrug thereof, wherein R1, R4-R8, R10, R2′-R6′, W, and A have any of the values described in the specification, as well as compositions comprising a compound of formula (I). The compounds are useful as antibacterial agents.... Agent:

20130116279 - Bicyclic heteroaryl inhibitors of pde4: The present invention relates to compounds and methods which may be useful as inhibitors of phosphodiesterase 4 (PDE4) for the treatment or prevention of inflammatory diseases and other diseases involving elevated levels of cytokines and proinflammatory mediators.... Agent: Kalypsys, Inc.

20130116280 - Fusion protein comprising c-terminal domain of ret protein and use thereof as a diagnosing marker: A fusion protein including N-terminal domain of a fusion partner at N-terminal and C-terminal domain of RET protein at C-terminal, a fusion gene encoding the fusion protein, and a use of the fusion protein or the fusion gene as a diagnosing marker for a cancer, are provided.... Agent: Macrogen Inc.

20130116281 - Multiphoton activable quinoline derivatives, their preparation and their uses: The present invention relates to multiphoton activable organic compounds responding to the following formula (I). The present invention also relates to a method of synthesizing the compounds of the invention, to an aqueous solution comprising at least one compound of the invention, and to their specific uses. The present invention... Agent:

20130116282 - Buckwheat extract enriched in d-fagomine: The buckwheat extract comprises a extract of buckwheat which are enriched in D-fagomine and including 3,4-di-epifagomine, a process for their preparation, pharmaceutical or veterinary compositions, dietary supplements or functional foods containing them, their use alone or in combination with saccharide, an iminocyclitol or probiotics, as a blood glucose levels controlling... Agent: Bioglane, S.l.n.e.

20130116283 - Substituted indole derivatives: Substituted indole derivatives, processes for the preparation thereof, medicinal products and pharmaceutical compositions containing these compounds and the use of substituted indole derivatives to treat pain and other conditions and for other medical purposes.... Agent: Gr&#xdc Nenthal Gmbh

20130116284 - Lipoic acid and nitroxide derivatives and uses thereof: Provided are bifunctional compounds comprising a poly(ADP-ribose) polymerase (PARP) inhibitor moiety and a reactive oxygen species (ROS) scavenger moiety, more particularly, a lipoic acid or cyclic nitroxide derivative, covalently attached either directly or via a linker, as well as pharmaceutical compositions comprising them. The compounds and pharmaceutical compositions are useful... Agent: Radikal Therapeutics Inc.

20130116285 - Chemical compounds: The invention relates to sulfonamide derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to a new sulfonamide Nav1.7 inhibitors of formula 10 (I):(I) or a pharmaceutically acceptable salt thereof, wherein Z,... Agent: Pfizer Limited

20130116286 - Droxidopa and pharmaceutical composition thereof for the treatment of neurally mediated hypotension: The present invention is directed to methods of treating neurally mediated hypotension. In particular, the invention provides pharmaceutical compositions comprising droxidopa alone, or in combination with one or more further active ingredients, that can be administered to a patient for the treatment of neurally mediated hypotension.... Agent: Chelsea Therapeutics, Inc.

20130116287 - Fungicide hydroximoyl-heterocycles derivatives: e

20130116289 - 5-(biphenyl-4-yl)-3-phenyl-1,2,4-oxadiazolyl derivatives as ligands on the sphingosine 1-phosphate(sip)receptors: The present invention provides compounds of Formula (I), as selective S1P1 inhibitors, as well as their use for treating multiple sclerosis and other diseases.... Agent: Merck Serono S.a.

20130116288 - Selective androgen receptor modulators: This invention provides compounds of formulas I, Ia, Ib, Ic, Id, Ie, If or Ig or salts thereof, pharmaceutical compositions comprising a compound of formulas I, Ia, Ib, Ic, Id, If or Ig and a pharmaceutically acceptable excipient, methods of modulating the androgen receptor, methods of treating diseases beneficially treated... Agent: Radius Health, Inc.

20130116291 - Association of xanthine oxidase inhibitors and statins and use thereof: The present invention relates to the association of active principles, i.e. of a xanthine oxidase inhibitor with one or more HMG CoA reductase inhibitors, pharmaceutical compositions comprising said active principles, for use in a human or veterinary therapeutic treatment, and methods for the preparation thereof.... Agent: Menarini International Operations Luxembourg S.a.

20130116290 - Use of dipeptidyl peptidase iv effectors for normalizing the blood glucose level in mammals: The present invention comprises the use of activity-reducing effectors of dipeptidyl peptidase (DP IV) and DP IV-analogous enzyme activity in the blood of a mammal to lower elevated post-prandial and basal blood glucose levels in mammalian organisms. The invention further comprises the use of activity-reducing effectors of dipeptidyl peptidase (DP... Agent:

20130116292 - Neurorestoration with r(+) pramipexole: Formulations and methods of use thereof for restoring neuronal, muscular (cardiac and striated) and/or retinal tissue function in children and adults afflicted with chronic neurodegenerative diseases, such as neurodegenerative movement disorders and ataxias, seizure disorders, motor neuron diseases, and inflammatory demyelinating disorders, are described herein. Examples of disorders include Alzheimer's... Agent: University Of Virginia Patent Foundation

20130116293 - High-throughput methods for determining pharmacological levels of plasma d-serine: Described herein are high-throughput methods of monitoring D-serine levels in plasma. The assay involves the use of strong cation solid phase extraction (SPE) to isolate D-serine from plasma, followed by quantitation of D-serine using the D-amino acid oxidase-(DAAO-) catalyzed reaction. Also described are methods of screening for compounds that act... Agent: The Johns Hopkins University

20130116294 - Pesticidal composition and its use: A composition comprising a carboxamide compound represented by following formula (I), wherein R1 represents a hydrogen atom or a methyl group, and R2 represents a methyl group, a difluoromethyl group or a trifluoromethyl group, and one or more phenylpyrazole compounds selected from group (A) consisting of fipronil and ethiprole is... Agent: Sumitomo Chemical Company, Limited

20130116295 - Antiparasitic formulations: Fipronil formulations and fipronil/S-methoprene co-formulations are provided herein. These formulations optionally contain one or more additional active ingredient(s). The formulations comprise an organic solvent, an alcohol co-solvent, and one or more antioxidants and without any crystallization inhibitor. The formulations provided herein are antiparasitic, and can be used, for example, to... Agent: Velcera Inc.

20130116296 - Pyrazole compound: wherein R1, R2, R3 and R4 are independently hydrogen or C1-6 alkyl etc.; R5 is C4-7 alkyl or —(CR8R9)r-E; R6, R7, R8 and R9 are independently hydrogen, fluorine or C1-6 alkyl; A is C6-10 aryl or heteroaryl etc.; r is 1, 2, 3 or 4; E is C3-8 cycloalkyl or... Agent:

20130116297 - Novel fusarisetin compounds, and use thereof: The present invention relates to novel fusarisetin compounds separated from Fusarium sp. FN080326 and having an anticancer activity, and to the use thereof. In detail, novel fusarisetin compounds separated and purified from Fusarium sp. FN080326, which is in turn separated from a soil sample, have an inhibitory activity on the... Agent: Korea Research Institute Of Bioscience And Biotechnology

20130116298 - Antitumor agent or postoperative adjuvant chemotherapeutic agent for hepatocellular carcinoma treatment: The present invention provides an antitumor agent or postoperative adjuvant chemotherapeutic agent for a hepatocellular carcinoma patient who has been treated by transarterial embolization. An antitumor agent or postoperative adjuvant chemotherapeutic agent comprising TSU-68 or a salt thereof, which can be administered to a hepatocellular carcinoma patient within 2 weeks... Agent: Taiho Pharmaceutical Co., Ltd.

20130116312 - Plasmalogen compounds, pharmaceutical compositions containing the same and methods for treating diseases of the aging: Described herein are routes of synthesis and therapeutic uses of 1-alkyl, 2-acyl glycerol derivatives of formula I: which when administered to mammalian biological systems result in increased cellular concentrations of specific sn-2 substituted ethanolamine plasmalogens independent of the ether lipid synthesis capacity of the system. Elevating levels of the specific... Agent: Phenomenome Discoveries Inc.

20130116313 - Compositions and methods for inhibiting g protein signaling: The present invention relates to methods for identifying agents which bind to specific amino acid residues of the protein interaction site of G protein β protein subunit. Compounds identified in accordance with the assay of the invention and methods for using the compound for modulating at least one activity of... Agent: University Of Rochester

20130116314 - Method of maintaining or improving the skin health of an animal comprising administering as a dietary supplement a composition comprising flax seed oil and gamma linolenic acid: A phytochemical composition for use as a veterinary dietary supplement comprising alpha linolenic acid (ALA) and up to 10% gamma linolenic acid (GLA). Preferably the ALA source is flax seed oil and GLA is sourced from borage oil.... Agent: Lintbells Ltd.

20130116315 - Composition for the prevention or treatment of obesity, dyslipidaemia, fatty liver or insulin resistance syndrome, comprising piperonal as an active ingredient: Provided is a composition for the prevention or treatment of obesity, dyslipidaemia, fatty liver or insulin resistance syndrome, comprising piperonal as an active ingredient. The composition of the present invention can be used to advantage as a drug or functional food composition which not only exhibits activity in the prevention... Agent:

20130116316 - Solid pharmaceutical compositions containing benzofuran derivatives: The present invention relates to a solid pharmaceutical composition for oral administration characterized in that it comprises a benzofuran derivative with antiarrhythmic activity, or one of the pharmaceutically acceptable salts thereof, as an active principle, and a pharmaceutically acceptable nonionic hydrophilic surfactant optionally in combination with one or more pharmaceutical... Agent: Sanofi

20130116317 - Furanyl compounds and the use thereof: Provided herein are substituted furanyl compounds of formula (I), pharmaceutical compositions comprising the compounds, methods of their preparation, and methods of their use. The compounds provided herein are useful for the treatment, prevention, and/or amelioration of various disorders, including cancer and proliferative disorders. In one embodiment, the compounds provided herein... Agent: Novomedix, LLC

20130116318 - Enzyme inhibitors: Compounds of formula (I) are inhibitors of histone deacetylase activity, and are useful in the treatment of, for example, cancers:... Agent: Chroma Therapeutics Ltd.

20130116319 - Agent for treating parkinson's disease: The present invention relates to the use of 3-methyl-6-(1-methylethenyl)cyclohex-3-ene-1,2-diol, its isomers and derivatives, as a compound for Parkinson disease treatment, that can be used in medicine. The compound is highly active, low toxic and can be synthesized from available natural compound α-pinene.... Agent: Ooo "tomskaya Farmatsevticheskaya Fabrika"

20130116321 - Composition containing serine as an active ingredient for the prevention and treatment of fatty liver diseases, and the use thereof: The present invention is related to a composition comprising a serine as an active ingredient for treating or preventing fatty liver diseases. The inventive compound significantly inhibits the SREBP-1 transcription activity involved in lipid synthesis and reduced the fatty liver formation through various in vitro test and in vivo test... Agent: Snu R&db Foundation

20130116320 - Gastric retentive gabapentin dosage forms and methods for using same: Provided is a method of treating a patient suffering from a pain state by administering to the patient a gastric retentive dosage form of gabapentin that is capable of administration in once-daily or twice daily dosing regimens. By reducing the need to administer gabapentin from the thrice-daily administrations characteristic of... Agent: Depomed, Inc.

20130116322 - Alkenyl naphthylacetic acids: and pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds of formula I are antagonists... Agent: Hoffmann-la Roche Inc.

20130116323 - Methods of improving or preserving lung function in a patient with a pulmonary disorder: The described invention provides methods for improving or preserving lung function in a patient suffering from a pulmonary disorder comprising an inflammatory component by administering to the patient a pharmaceutical composition comprising a therapeutic amount of N-acetylcysteine, a derivative of N-acetylcysteine, or a pharmaceutically acceptable salt of N-acetylcysteine, wherein the... Agent: The Leland Stanford Junior University

20130116324 - Pharmaceutical composition for the prevention or treatment of inflammatory diseases or immune diseases containing ramalin: The present invention relates to the novel use (anti-inflammatory activity) of Ramalin isolated from the Antarctic lichen Ramalina terebrata, and more specifically to a pharmaceutical composition containing Ramalin as an active ingredient. Ramalin of the invention is a compound derived from natural material, has no toxicity or side effects, and... Agent: Korea Ocean Research And Development Institute

20130116325 - Compositions and methods for treating anhidrosis: Provided herein are compositions and methods useful for the treatment of anhidrosis in mammals, for example, horses.... Agent:

20130116326 - Treatment of delayed cutaneous hypersensitivity conditions with s-farnesylthiosalicylic acid and analogs thereof: Disclosed are methods of treating a mammalian subject afflicted with a delayed cutaneous hypersensitivity condition, comprising administering to the subject a pharmaceutical composition comprising an effective amount of S-farnesylthiosalicylic acid (FTS) or a structural analog thereof, and compositions for use in the methods.... Agent: Ramot At Tel-aviv University Ltd.

20130116327 - Burst drug release compositions: A solid dose composition comprising at least one pharmaceutically active ingredient and at least one controlled release agent and method of manufacturing said composition is disclosed. The burst profile of at least one pharmaceutically active ingredient in the composition is regulated by the apparent viscosity of the controlled release agent... Agent: Wyeth LLC

20130116328 - Thermogelling anaesthetic compositions: The present invention relates to a thermogelling pharmaceutical composition comprising local anaesthetics in base form and which is suitable for topical administration. The compositions further comprise a polyoxyethylene castor oil and one or more surfactants to obtain thermogelling characteristics.... Agent: Pharmanest Ab

20130116329 - Treatment for reducing inflammation: A method of treating endometriosis in a person by reducing a cytokine MCP-1 related activity level of an endometriosis implant in said person by 50% or more while not affecting a corresponding TNF-α related activity level by more than comprises providing a pharmaceutical composition comprising a local anaesthetic, in particular... Agent: Isifer Ab

20130116330 - Colchicine solid-state forms; methods of making; and methods of use thereof: Disclosed are new colchicine solid-state forms, methods of preparing the solid-state forms, as well as formulations prepared therefrom and uses thereof.... Agent:

20130116331 - Medical gel: This application pertains to antimicrobial medical gel compositions, the compositions comprising: (a) a gelling agent comprising etherified hydroxyethylcellulose; (b) an antimicrobial agent, specifically the quaternary ammonium compound benzalkonium chloride; (c) a solvent, propanediol being preferred; and (d) water. The compositions through their antimicrobial effectiveness address the problem of cross-contamination leading... Agent: Brusells Ventures Corp.

20130116332 - Formulations, salts and polymorphs of transnorsertraline and uses thereof: Provided herein are pharmaceutical compositions comprising transnorsertraline, salts and polymorphic forms of transnorsertraline, methods of making the compositions, and methods for their use for the treatment of CNS diseases, including depression.... Agent:

20130116333 - Solid tapentadol in non-crystalline form: The invention relates to solid tapentadol in non-crystalline form together with a surface stabiliser in the form of a stable intermediate. In the intermediate of the invention, tapentadol is preferably present in amorphous form or in the form of a solid solution. The invention further relates to methods of producing... Agent: Ratiopharm Gmbh

20130116334 - Treatment of irritable bowel syndrome: A method of treating irritable bowel syndrome in a patient in need thereof by administering to said patient a pharmaceutically effective amount of tapentadol.... Agent: Gruenenthal Gmbh

20130116335 - Method for identifying therapeutic agents for treatment of cancer: The presence of phosphorylated Cdc27 in cancer cells is utilized to identify patients likely to benefit from treatment with a chemotherapeutic agent that binds to, or binds to and crosslinks, phosphorylated Cdc27, e.g., curcumin, or to determine whether patients undergoing such treatment will continue to respond effectively. Candidate compounds are... Agent: The Nemours Foundation

20130116336 - Treatment of ataxia telangiectasia: The present invention relates to methods of treating Ataxia-Telangiectasia (A-T) or Ataxia-telangiectasia like disorder (ATLD) with compounds such as tocotrienol quinones and tocotrienol hydroquinones, including alpha-tocotrienol quinone, in order to alleviate symptoms of the disease.... Agent:

20130116337 - Methods and compositions for treating conditions mediated by oxidative stress or electrophilic environmental toxins: Methods and compositions are disclosed for treating a subject with a disease or tissue injury mediated by cellular oxidative stress or with an environmental toxicity due to an electrophilic toxicant or pollutant, and for providing a nutritional supplement to a subject and for providing a skin treatment for a subject,... Agent:

20130116338 - Nanometal dispersion and method for preparing the same: A nanometal dispersion and a method for preparing a nanometal dispersion are provided. The method comprises the following steps: providing a first solution containing a metal ion; providing a second solution containing inulin; mixing the first solution and the second solution to provide a third solution; and providing energy to... Agent: China Medical University

20130116339 - Method for magnetising natural and synthetic aluminosilicates: Procedure for the magnetization of different inorganic surfaces, whether natural or synthetic, such as aluminosilicates, both synthetic and natural (natural zeolites, synthetic zeolites, alumina, allophane, among others) that give magnetic properties to those surfaces. Objectives of the present application are also the above mentioned surfaces, magnetized, and their different uses.... Agent: Universidad De Santiago De Chile

20130116340 - Cosmetic and topical skin preparation comprising higher alcohol-modified silicone: A cosmetic and a topical skin preparation comprising a higher alcohol-modified silicone (A) with the following general formula (1) wherein R1 is, e.g., an alkyl group; P is a monovalent organic group that contains the Si—O bond or is a long-chain monovalent hydrocarbyl group; at least one Q is a... Agent: Dow Corning Toray Co., Ltd.

20130116341 - In-vivo gelling pharmaceutical pre-formulation: Provided herein are in vivo gelling pharmaceutical pre-formulations forming biocompatible hydrogel polymers that are polymerized in vivo and kits comprising at least one nucleophilic compound or monomer unit, at least one electrophilic compound or monomer unit, and optionally at least one therapeutic agent. The biocompatible hydrogel polymer is bioabsorbable and... Agent: Medicus Biosciences, LLC

20130116342 - Salt-resistant emulsions: The invention relates to methods of modulating the stability of emulsions, especially the stability of emulsions to flocculation and coalescence. The use of peptide emulsifiers comprising at least one side chain carboxylate group in preparing emulsions that are stable to flocculation or coalescence in the presence of salt is also... Agent: Pepfactants Pty Ltd

20130116344 - Nucleic acids and methods for detecting turfgrass pathogenic fungi: e

20130116343 - Salivary protein markers for detection of breast cancer: A method of diagnosing a patient's risk of breast cancer comprises measuring in a saliva sample from the patient a concentration of at least a first protein marker, wherein the first protein marker is either ubiquitin or cytochrome p450, to provide a set of test data comprising a concentration value... Agent: Board Of Regents Of The University Of Texas System